Background

Infectious diseases - focus of her work

For almost two decades Margaret’s work has centred around infectious diseases, preventing their transmission and identifying the impact of these infections in vulnerable populations. A researcher and clinician, her principal research interests are in the epidemiology of blood-borne viruses (BBVs) HIV, hepatitis B and hepatitis C, sexually transmitted infections, and improving the management of individuals who already have the infection.

Margaret has considerable experience in undertaking community-based research involving young people, injecting drug users (IDUs) and vulnerable populations, and experience in research in tertiary care institutes. She also has considerable experience in undertaking research that used new technologies (such as SMS, Facebook) for health promotion and prevention interventions.

Translational Research

Margaret’s work and that of others on the feasibility of treating current injecting drug users for their HCV, led to changes in the clinical management of people who injected drugs infected with HCV in Australia.

Margaret and her research group identified high rates of hepatitis C reinfection in people who inject drugs. This has led to changes in health education and prevention in this area.

Margaret has also has been instrumental in the development of innovative sentinel surveillance systems for BBVs and STIs both within Victoria and nationally. She and her group are world leaders in research using new technologies such as SMS and social networking sites for health promotion.

She has been a member of numerous advisory committees and working groups related to HCV, HBV and HIV including WHO and other international Working Groups and Advisory Committees, and National and Victorian working groups, taskforces and advisory committees.

With more than $50 million in competitive research grants and tenders, Margaret has in excess of 350 peer-reviewed publications and has won a number of prizes for her work.

Centre for Research Excellence into Injecting Drug Use (CREIDU).

Margaret was one of the Chief Investigators and also on the Executive of the NHMRC project grant - CREIDU - from 2010-2015.

• M Hellard, P Dietze, A Ritter, D Lubman, S Kinner, G Williams, G Dore, L Maher, D Moore, R Power. Centre for Research Excellence Reducing the health, social and economic burden of injecting drug use in Australia. NHMRC 2010 – 2015 $2,485,060

Most significant publications

1. N Scott, M Stoove, S Kelly, D Wilson, M Hellard. Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia (In press – CID) Accepted July 2017 This recently accepted publication outlines the difficulties Australia will have in obtaining the goal of ending HIV by 2030 without significant increases in programs such as pre-exposure prophylaxis, testing and treatment.
2. Lim MSC, et al. (senior author) Young Australians’ use of pornography and associations with sexual risk behaviours. Aus NZ J Pub Health 2017. This Australian first study young people found that pornography viewing was very common and was associated with younger age at first sex, non-heterosexual identity, ever having anal intercourse, and recent mental health problems. The work has been cited extensively in senate and parliamentary enquiries
3. N Scott, J Doyle, D Wilson, A Wade, J Howell, A Pedrana, A Thompson, M Hellard, Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. International Journal of Drug Policy, 2017; 47, 107-116 This important model highlights the importance of upscaling testing if we are to achieve hepatitis C elimination in Australia and globally.
4. K Dolan et al. Global burden of HIV, viral hepatitis and tuberculosis among prisoners and detainees. Lancet 2016. 388: 10049, 1089–1102 (Cit 55) This major review highlighted prisons as a high risk environment for BBVs and TB, and the importance of prevention and treatment programs.
5. N Scott, E McBryde, A Thompson, J Doyle, M Hellard. Treatment scale-up to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model. Gut 2017; Gut 66 (8), 1507-1515 Cit 20 This important model providing guidance to the government about the numbers of PWID who require treatment annually to achieve hepatitis C elimination as a public health goal. The methods used in the model have been used in Iceland, and are being used in Myanmar and India to model hepatitis C elimination.
6. Hellard et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatol 2014; 60:1861-1870 (Cit: 59) This recently published ground-breaking paper showed that treating PWID and their injecting network impacts on HCV incidence and transmission. The findings led to the funding of the TAP Study, a world first ‘treatment as prevention’ intervention using a network-based approach.
7. N Martin et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals, Hepatology, 2013; 58:1598-1609 (Cit 274) I played a central role in this international collaboration of this highly cited paper that uses mathematical modelling to inform the elimination of HCV in people who inject drugs.
8. 1. Aspinal et al (senior author). Treatment of HCV infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clin Infect Dis 2013;57:s80-s89 (Cit 177). This paper complemented earlier work by my team showing PWID can be successfully treated for HCV.
9. Sacks-Davis et al. (Senior Author) High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS One 2013; v8(11). (Cit: 33 ) This important paper highlighted the dynamic nature of hepatitis C infection/reinfection. It provided insights into the transmission of infection within cohorts of PWID and the network impact of transmission.
10. J Grebely et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infectious Diseases 2012, 12: 408-414 (Cit 124) This paper provides important insight into what will be required to develop, trial and successfully implement a hepatitis C vaccine in PWID
11. Lim M et al. A randomised controlled trial of the impact of text and email messaging on the sexual health of young people. J Epi Comm Health 2012;66:69-74 . Cit – 125 This world-first randomised controlled trial in a community-based setting found that SMS could be used to increase sexual health knowledge and health-seeking behaviour.
12. A Pedrana et al. High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia. J AIDS 2012;59:94–99. Cit – 45 This paper identified that a significant proportion (30%) of HIV positive MSM did not know their HIV status leading to the development of new health promotion campaign for Victoria.
13. GV Matthews et al. Patterns and characteristics of hepatitis C transmission clusters amongst HIV positive and HIV negative individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2011;52(6):803–811 Cit 54 This paper provided important evidence about hepatitis C transmission in gay and bisexual men (GBM) in Australia. It informed hepatitis C elimination programs in this population; informed by this work I currently lead a hepatitis C elimination program in Melbourne and I recently established a global collaboration for hepatitis C elimination in HIV coinfection.
14. Gold et al. Hellard. Determining the impact of text messaging for sexual health promotion to young people. Sex Transm Dis 2011;38(4):247-52 (Cit: 77) This large scale implementation study of over 6000 young people confirmed that SMS could be successfully used as a health promotion tool, outside of a formal clinical trial setting.
15. Gold J et al. A Systematic Examination of the Use of Online Social Networking Sites for Sexual Health Promotion. BMC Public Health 2011, 11:58 Cit – 153 This world first study evaluated the use of online social networking sites as health promotion tools. Importantly it established a framework for evaluating online programs into the future. Cit – 153
16. Dore, Hellard et al. Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection. Gastroenterol 2010; 138:123–135 Cit: 139 I was the major recruiter for the ATAHC Study, the largest study of acute HCV in PWID. We showed that treatment of current PWID was successful, even if they continued to inject drugs whilst on therapy
17. R Guy et al. Does the frequency of HIV and STI testing among MSM in primary care adhere with Australian guidelines? STI, 2010;86: 371-376 (Cit: 46) Senior Author This paper identified low levels of HIV testing in MSM and is informing Australia’s HIV elimination response highlighting the importance of improving access to HIV testing
18. Hellard et al. Hepatitis C treatment for injecting drug users: a review of the available evidence. Clin Infect Dis 2009; 49:561–7. Cit: 215 This highly cited systematic review was the first study to clearly identify that PWIDs’ response to HCV treatment was equivalent to non-injectors’; it informed national and international HCV guidelines, impacting on clinicians management and increasing PWIDs access to treatment
19. Aitken et al. (Senior Author) High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatol 2008; 48:1746-52. Cit: 125 This important paper was one of the first in the world to show that HCV reinfection is common and HCV infection is far more dynamic than previously recognised. The work is informing HCV elimination models and vaccine development
20. Hellard M et al. A randomized blinded controlled trial investigating the gastrointestinal health effects of drinking water quality. Environ Health Perspectives. 2001; 109:773-778. Cit: 194.

Appointments

• 2017: Deputy Director (Programs), Burnet Institute
• 2013: Associate Director, Burnet Institute
• 2012: Adjunct Professor, Monash University, DEPM.
• 2011: Head, Hepatitis Services, Infectious Disease Unit, Alfred Hospital, Victoria, Australia
• 2009: NHMRC Senior Research Fellow
• 2008: Honorary Senior Fellow, Nossal Institute, University of Melbourne, Victoria, Australia
• 2006: Honorary Associate Professor, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
• 2002-2006: Honorary Senior Lecturer, Department of Epidemiology and Preventive Medicine, Monash University, Australia
• 2002: Head of the Epidemiology and Social Research Unit (now Centre for Population Health) at Burnet Institute, Melbourne, Victoria, Australia
• 2001-2009: Infectious Diseases Physician, Royal Melbourne Hospital, Victoria, Australia
• 2000-2002: Senior Research Fellow, Department of Epidemiology and Preventive Medicine, Monash University, Australia
• 1996: Infectious Diseases Physician, Alfred Hospital, Melbourne, Australia

Positions

1. Red Cross Blood Bank Australia – Chair Expert Review Panel on Injecting Drug User Donation Policy
2. Advisory Committee to Justice Health on Hepatitis C Care and Treatment Victoria
3. WHO Advisor –Think tank to develop strategies to eliminate hepatitis B and C
4. WHO Advisor – Hepatitis C Surveillance and Screening
5. WHO Temporary Advisor - WHO Consultation on Strategic use of ARVs
6. WHO Temporary Advisor – WHO Consultation on Hepatitis C Modelling
7. Communicable Diseases Network of Australia National Strategies BBV/STI Subcommittee
8. InC3 – International Collaboration of Incidence Hepatitis C in Injection Drug users (coordinating committee).
9. Australian Hepatitis Councils Health Reference Group
10. Victorian Department of Health Advisory Committee on BBVs and STIs
11. ASHM Viral Hepatitis Clinical Oversight Committee

Qualifications

• 2001: FAFPHM, Australasian Faculty of Public Health Medicine
• 2000: PhD, Department of Epidemiology and Preventive Medicine, Monash University
• 1996: FRACP, Royal Australasian College of Physicians
• 1986: MBBS, Monash University

Awards

• 2019: Member of the Order of Australia (AM) ‘for significant service to medicine as an infectious diseases and public health physician and research scientist’.
• 2010: Burnet Institute Frank Fenner Award: Recognised for her outstanding leadership, innovation and contribution to the fields of research and public health
• 2005: Victorian Public Health Award, Program excellence winner for HIV sentinel surveillance
• 2005: VicHealth Award for Outstanding Achievement in Health Promotions (studies over $75,000) for The epidemiology and control of chlamydia infection in Victoria
• 2005: VicHealth Award for Outstanding Achievement in Health Promotions (studies less than $15,000) for Uncontested possessions and key positions
• 2005: Frank Fenner Award for Advanced Research in Infectious Diseases
• 2004: NHMRC Career Development Award
• 2004: VicHealth Senior Research Fellowship
• 2001: Australasian Society of Infectious Diseases, Aztra Zeneca Travel Award
• 2000: Inaugural Graham Rouch Award, Victorian Branch of the Australasian Faculty of Public Health Medicine
• 2000: Young Water Scientist of the Year
• 2000: Victorian Public Health Award for Research Excellence
• 2000: NHMRC Clinical Research Fellowship
• 1998: NHMRC Clinical Research Fellowship

Projects (39)

Current (22)

• ACCESS: STI and BBV surveillance system
  ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
• co-EC Study: Eliminating hepatitis C/HIV coinfection
  Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
• CREIDU: Centre for Research Excellence into Injecting Drug Use
  Improving the health of PWID through new research to inform public health policy and practice.
• CT2 Study: Community-based Testing and Treatment for Hepatitis C
  This hybrid trial is underway in Myanmar.
• DARE C: ATAHC II Substudy
  DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
• EC Australia: The vital missing link to eliminating hepatitis C
  Australia’s first nationally coordinated response to hepatitis C aims to achieve elimination by 2030.
• EC Partnership: Eliminate Hepatitis C Partnership
  Informing the elimination of HCV through a community-based nurse-led model of care and treatment.
• Eliminate Hepatitis C Australia Partnership
  Bringing together researchers, implementation scientists, government, health services and community organisations to increase hepatitis C testing and treatment across Australia.
• Exploring alcohol and other drug use among migrant communities in Victoria
  A qualitative study supported by the Wyndham City Council.
• HCV Elimination Modelling
  Providing evidence-based policy recommendations for prevention, testing and treatment of Hepatitis C.
• Healthy Mothers, Healthy Babies
  A collaborative research program aimed at providing life-saving health care for women and children in PNG.
• Hepatitis C and injecting networks
  Understanding the transmission of hepatitis C in a social network of young people who inject drugs.
• Improving Hepatitis B Virus screening in general practice in Victoria
  Knowledge, attitudes and practices of HBV screening by GPs in Victoria, and an intervention to improve screening among priority populations.
• Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals
  A cohort of women was exposed to hepatitis C virus (HCV) in a health care setting to a common source. The source was chronically infected with HCV genotype 1b.
• Pornography and Young People
  Exploring trends in pornography use among young people in the Australian context.
• Sex, Drugs, and Rock'n'Roll (Big Day Out Study)
  A landmark study since 2005 of young people's risk behaviours including sex, drug use and alcohol.
• SHARP: Screening for Hepatitis in At-Risk Populations
  A collaborative project between Burnet Institute and Cancer Council Victoria.
• Social Networks and the Hepatitis C Virus
  The Networks study aims to produce a better understanding of the structure and dynamics of IDU networks to see if they can be altered to reduce HCV entry and spread.
• The Australian Trial in Acute Hepatitis C (ATAHC)
  An NIH-funded multicentre prospective cohort study conducted from 2004-2008 in Australia, featuring 167 subjects.
• The B-VAX Project: Hep B vaccinations for people who inject drugs
  Using assertive outreach to provide hep B vaccinations for people who inject drugs.
• TRYP: Transitions and Risk in Young People project
  Investigating the influence of peer groups on behaviour in the transition from adolescence to adulthood.
• Understanding how HCV evades the immune system
  This project aims to understand the quality of the immune response in those people who are protected from developing chronic HCV despite frequent exposure.

Past (17)

• ATAHC 2: Australian Trial in Acute Hepatitis C II
  The ATAHC 2 study will examine the effect of interferon with or without Ribavirin in recent HCV infection.
• COUNT: Community-based undiagnosed infection and HIV testing study
  Identifying undiagnosed HIV infection among Australian gay men while delivering HIV testing.
• DAA based therapy for recently acquired hepatitis C – II (DARE-C II)
  To evaluate the combination of SOF plus RBV in patients with recently acquired HCV infection.
• Defining sexual transmission of hepatitis C among gay men
  Defining risk and mechanisms of transmission for acute HCV infection within high-risk populations.
• Eliminating hepatitis C infection in Victoria through treatment scale up
  The project will aim to explore the supports needed for prescribers to start treatment for HCV infection.
• Evaluation of a condom distribution trial in Victorian prisons
  The evaluation of a pilot program introducing condoms and dental dams into Victorian Prisons.
• Examining hepatitis C reinfection among HIV co-infected gay and bisexual men
  This project will examine gay and bisexual men’s knowledge toward risk taking and hep C prevention.
• FaceSpace: Using social networking to promote safer sex to higher risk groups
  This project aims to use social networking to deliver health messages to higher risk groups.
• Opportunities to improve the health of behaviourally bisexual men in Vientiane, Laos
  Men with bisexual behaviour in Laos engage in high-risk behaviours with low access to sexual health care.
• Rapid-EC hepatitis C Pilot Study
  Investigating the feasibility of providing rapid point-of-care testing for hepatitis C in community clinics.
• SEXT ME UR (.)(.) An investigation of the prevalence and practice of sexting among young Australians
  ‘Sexting’ is the sending of sexual content via phone or online. This project will examine how common sexting is among young Australians.
• SMS for Health: An acceptability trial of SMS to deliver adolescent sexual and reproductive health and anti-smoking messages to young people in Indonesia
  The trial is investigating whether communication technologies can be used to improve sexual and reproductive health knowledge and awareness, access and utilisation of services, and improve awareness of harms related to smoking, in Indonesia.
• Social networking sites for sexual health promotion: a review
  Identifying strategies for the use of social networking websites in sexual health promotion.
• TAP: Treatment and Prevention Hep C study
  Does treating people who inject drugs for their hep C reduce transmission and prevalence?
• The Prime Study: Treating hep C in primary healthcare setting
  Examining feasibility of treating people with genotype 1 hepatitis C in primary healthcare setting.
• WASH: Interventions for monastic schools in Myanmar
  Evaluating the impact of a water, sanitation and hygiene program across three states of Myanmar.
• WHISPER and SHOUT - mHealth interventions among Kenyan sex workers
  Mobile phone-based health promotions sent to sex workers in Mombasa.

Publications (412)

2019 (40)

• Prevalence of daily tobacco smoking participation among HIV-positive and HIV-negative Australian gay, bisexual and other men who have sex with men.
  Wilkinson A, Quinn B, Draper B, White S, Hellard M, Stoové M
  HIV Med. 2019 Oct; Epub ahead of print
• Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
  Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, 7, 8, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team
  Clin Infect Dis. 2019 Oct; Epub ahead of print
• Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
  Papalucaa T, .O’Keefe J, Bowden S, Doyle JS, Stoové M, Hellard M, Thompson AJ
  J Clin Virol. 2019 Oct; 120:84-87
• Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
  Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, Pemberton D, Hellard ME, Doyle JS
  Int J Drug Policy. 2019 Oct; 72:195-198
• Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
  Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
  Int J Drug Policy. 2019 Oct; 72:91-98
• A comparative, retrospective analysis of HIV testing among gay, bisexual and other men who have sex with men in Melbourne, Australia.
  Ryan KE, Wilkinson AL, Chow E, Read T, Chen M, Locke P, Leitinger D, Bradshaw C, Pedrana A, Hellard M, Fairley CK, Stoové M
  Aust N Z J Public Health. 2019 Oct; 43(5):419-423
• The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
  Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME
  BMC Med. 2019 Sep; 17(1):175
• ‘Not my child’: parenting, pornography, and views on education.
  Davis AC, Wright C, Curtis M, Hellard ME, Lim MSC, Temple-Smith MJ
  J Fam Studies. 2019 Sep; Epub ahead of print
• Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics.
  Callander D, Guy R, Fairley CK, McManus H, Prestage G, Chow EPF, Chen M, Connor CCO, Grulich AE, Bourne C, Hellard M, Stoové M, Donovan B
  Sex Health. 2019 Sep; 16(5):457-463
• Sexually transmissible infections among transgender men and women attending Australian sexual health clinics.
  Callander D, Cook T, Read P, Hellard ME, Fairley CK, Kaldor JM, Vlahakis E, Pollack A, Bourne C, Russell DB, Guy RJ, Donovan B
  Med J Aust. 2019 Aug; Epub ahead of print
• A Health Education Website Developed to Meet Young People's Information Needs About Web-Based Pornography and Sharing of Sexually Explicit Imagery (SCOPE): Usability Study.
  Davis AC, Wright CJC, Temple-Smith MJ, Hellard ME, Lim MSC
  JMIR Form Res. 2019 Aug; 3(3):e12824
• Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program.
  Makuza JD, Liu CY, Ntihabose CK, Dushimiyimana D, Umuraza S, Nisingizwe MP, Umutesi J, Serumondo J, Mugeni SD, Semakula M, Gupta N, Hellard M, Nsanzimana S
  BMC Infect Dis. 2019 Aug; 19(1):688
• Assessment of service refinement and its impact on repeat HIV testing by client's access to Australia's universal healthcare system: a retrospective cohort study.
  Ryan KE, Wilkinson AL, Asselin J, Leitinger DP, Locke P, Pedrana A, Hellard M, Stoové M
  J Int AIDS Soc. 2019 Aug; 22(8):e25353
• Retreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
  Papaluca T, Sinclair M, Gow P, Pianko S, Sievert W, Arachchi N, Cameron K, Bowden S, O'Keefe J, Doyle J, Stoove M, Hellard M, Iser D, Thompson A
  Liver Int. 2019 Jul; Epub ahead of print
• Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies.
  Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J
  Clin Infect Dis. 2019 Jul; Epub ahead of print
• Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
  Averhoff F, Lazarus JV, Sergeenko D, Colombo M, Gamkrelidze A, Tsertsvadze T, Butsashvili M, Metreveli D, Sharvadze L, Hellard M, Gnes S, Gabunia T, Nasrullah M
  J Hepatol. 2019 Jul; 71(4):645-647
• Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.
  Abayasingam A, Leung P, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd A, Rodrigo C
  Infect Genet Evol. 2019 Jul; 71:36-41
• Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Clin Infect Dis. 2019 Jun; Epub ahead of print
• Clinical outcomes of a cohort of migrants and citizens living with human immunodeficiency virus in Botswana: implications for Joint United Nation Program on HIV and AIDS 90-90-90 targets.
  Marukutira T, Yin D, Cressman L, Kariuki R, Malone B, Spelman T, Mawandia S, Ledikwe JH, Semo BW, Crowe S, Stoove M, Hellard M, Dickinson D
  Medicine. 2019 Jun; 98(23):e15994
• Pathology laboratory surveillance in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) of sexually transmitted infections and blood borne viruses: Study Protocol.
  van Gemert C, Guy R, Stoove M, Dimech W, El-Hayek C, Asselin J, Moreira C, Nguyen L, Callander D, Boyle D, Donovan B, Hellard M
  J Med Internet Res. 2019 May; 8(8):e13625
• Scale-up of hepatitis C treatment in prisons is key to national elimination.
  Papaluca T, Hellard ME, Thompson AJV, Lloyd AR
  Med J Aust. 2019 May; 210(9):391-393
• "I'm obviously not dying so it's not something I need to sort out today": Considering hepatitis C treatment in the era of direct acting antivirals.
  Wright C, Cogger S, Hsieh K, Goutzamanis S, Hellard M, Higgs P
  Infect Dis Health. 2019 May; 24(2):58-66
• Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
  Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, Tee BK, Fairley CK, Chang CC, Armishaw J, Vujovic O, Penn M, Cundill P, Forgan-Smith G, Gall J, Pickett C, Lal L, Mak A, Spelman TD, Nguyen L, Murphy DA, Ryan KE, El-Hayek C, West M, Ruth S, Batrouney C, Lockwood JT, Hoy JF, Hellard ME, Stoové MA, Wright EJ; PrEPX Study Team
  JAMA. 2019 Apr; 321(14):1380-1390
• People who inject drugs in Bangladesh - the untold burden!
  Khan SI, Reza MM, Crowe SM, Rahman M, Hellard M, Sarker MS, Chowdhury EI, Rana AM, Sacks-Davis R, Banu S, Ross AG
  Int J Infect Dis. 2019 Mar; 83:109-115
• Tracking the uptake of outcomes of hepatitis B virus testing using laboratory data in Victoria, 2011-2016; a population-level cohort study.
  van Gemert C, Dimech W, Stoové M , Guy R , Howell J , Bowden S, Nicholson S , Pendle S , Donovan B , Hellard M
  Sexual Health. 2019 Mar; 16:358-366
• Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study.
  Winter RJ, Stoové M, Agius PA, Hellard ME, Kinner SA
  Drug Alcohol Rev. 2019 Mar; 38(3):254-263
• Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
  Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.
  Clin Infect Dis. 2019 Feb; Epub ahead of print
• Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
  Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME
  J Viral Hepat. 2019 Feb; 26(7):919-922
• Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004-2015.
  McManus H, Callander D, Donovan B, Russell DB, O'Connor CC, Davies SC, Lewis DA, Hellard ME, Chen MY, Petoumenos K, Varma R, Cogle A, Boyd MA, Grulich A, Pollard J, Medland N, Fairley CK, Guy RJ
  Med J Aust. 2019 Feb; 210(6):269-275
• HIV diagnoses in migrant populations in Australia-A changing epidemiology.
  Gunaratnam P, Heywood AE, McGregor S, Jamil MS, McManus H, Mao L, Lobo R, Brown G, Hellard M, Marukutira T, Bretaña NA, Lang C, Medland N, Bavinton B, Grulich A, Guy R
  PLoS One. 2019 Feb; 14(2):e0212268
• Estimating the syphilis epidemic among gay, bisexual and other men who have sex with men in Australia following changes in HIV care and prevention.
  Wilkinson A, Scott N, Tidhar T, Luong P, El-Hayek C , Wilson D, Fairley C, Zhang L, Leslie D , Roth N , Tee BK , Hellard M , Stoové M
  Sex Health. 2019 Feb; 16(3):254-262
• Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
  Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts TR, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners.
  Lancet Gastroenterol Hepatol. 2019 Feb; 4(2):135-184
• A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015.
  Bartlett SR, Applegate TL, Jacka BP, Martinello M, Lamoury FM, Danta M, Bradshaw D, Shaw D, Lloyd AR, Hellard M, Dore GJ, Matthews GV, Grebely J
  J Int AIDS Soc. 2019 Feb; 22(2):e25222
• Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
  Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoové M, Hellard M, Iser D, Thompson A
  J Hepatol. 2019 Jan; 70(5):839-846
• Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
  Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).
  Liver Int. 2019 Jan; 39(1):20-30
• Genomic variability of within-host hepatitis C variants in acute infection.
  Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative
  J Viral Hepat. 2019 Jan; Epub ahead of print
• Aiming for the elimination of viral hepatitis in Australia, New Zealand, the Pacific Islands and Territories: where are we now and barriers to meeting WHO targets by 2030.
  Howell J, Pedrana A, Cowie BC, Doyle J, Getehun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
  J Gastroenterol Hepatol. 2019 Jan; 34(1):40-48
• Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
  Goutzamanis S, Doyle J, Higgs P, Hellard M
  J Viral Hepat. 2019 Jan; 26(2):218-223
• The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.
  Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J
  J Virus Erad. 2019 Jan; 5(1):60-66
• Injection drug network characteristics as a predictor of injection behaviour.
  Spelman T, Sacks-Davis R, Dietze P, Higgs P, Hellard M
  Epidemiol Infect. 2019 Jan; 147:e173

2018 (42)

• Monitoring the Control of Sexually Transmissible Infections and Blood-Borne Viruses: Protocol for the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS).
  Callander D, Moreira C, El-Hayek C, Asselin J, van Gemert C, Watchirs Smith L, Nguyen L, Dimech W, Boyle DI, Donovan B, Stoové M, Hellard M, Guy R
  JMIR Res Protoc. 2018 Nov; 7(11):e11028
• Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
  Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group
  Int J Drug Policy. 2018 Oct; 62:94-103
• Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
  Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P
  Lancet Infect Dis. 2018 Oct; 18(12):1397-1409
• Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
  Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group
  Int J Drug Policy. 2018 Oct; 62:14-23
• Aiming for 90-90-90 - the importance of understanding the risk factors for HIV exposure and advanced HIV infection in migrant populations and other groups who do not report male-to-male sex.
  Peach E, Lemoh C, Stoové M, Agius P, El Hayek C, Higgins N, Hellard M
  Sex Health. 2018 Oct; 15(5):441-450
• Blood-borne virus transmission in an urban, culturally diverse neighbourhood: results from a cross-sectional bio-behavioural survey using innovative outreach methods in a hard-to-reach population.
  Peach E, Cogger S, Byron K, Francis P, O'Keefe D, Higgs P, Stoove M, Elmore K, Dietze P, Hellard M
  Sex Health. 2018 Oct; 15(1):54-60
• Pathways to ensure universal and affordable access to hepatitis C treatment.
  Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M
  BMC Med. 2018 Oct; 16(1):175
• Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia.
  Richmond JA, Ellard J, Wallace J, Thorpe R, Higgs P, Hellard M, Thompson A
  Hepatol Med Policy. 2018 Aug; 3:8
• Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model.
  Scott N, Ataide R, Wilson DP, Hellard M, Price RN, Simpson JA, Fowkes FJI
  Malar J. 2018 Aug; 17(1):279
• Evolutionary study and phylodynamic pattern of human influenza A/H3N2 virus in Indonesia from 2008 to 2010.
  Agustiningsih A, Trimarsanto H, Restuadi R, Artika IM, Hellard M, Muljono DH
  PLoS One. 2018 Aug; 13(8):e0201427
• Safe sex in chick lit: a ‘novel’ analysis of sexual health references in popular women’s fiction.
  Lim MSC, Hellard ME, Horyniak
  Sex Health. 2018 Jul; 15(5):468-472
• Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
  Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
  J Viral Hepat. 2018 Jul; 25(12):1472-1480
• Mobile Phone-Based Ecological Momentary Intervention to Reduce Young Adults' Alcohol Use in the Event: A Three-Armed Randomized Controlled Trial.
  Wright C, Dietze PM, Agius PA, Kuntsche E, Livingston M, Black OC, Room R, Hellard M, Lim MS
  JMIR Mhealth Uhealth. 2018 Jul; 6(7):e149
• Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Trials. 2018 Jul; 19(1):383
• Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.
  Popping S, El-Sayed M, Feld J, Hatzakis A, Hellard M, Lesi O, Ninburg M, Ward J, Boucher C
  J Virus Erad. 2018 Jul; 4(3):193-195
• Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
  Hainsworth SW, Dietze PM, Wilson DP, Sutton B, Hellard ME, Scott N
  PLoS One. 2018 Jun; 13(6):e0198336
• Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
  Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M
  Lancet Glob Health. 2018 Jun; 6(6):e659-e667
• Measuring and understanding the attitudes of Australian gay and bisexual men towards biomedical HIV prevention using cross-sectional data and factor analyses.
  Wilkinson AL, Draper BL, Pedrana AE, Asselin J, Holt M, Hellard ME, Stoové M
  Sex Transm Infect. 2018 Jun; 94(4):309-3014
• Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?
  Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME
  Expert Rev Anti Infect Ther. 2018 May; 16(5):411-422
• Implications of survey labels and categorisations for understanding drug use in the context of sex among gay and bisexual men in Melbourne, Australia.
  Ryan KE, Wilkinson AL, Pedrana A, Quinn B, Dietze P, Hellard M, Stoové M
  Int J Drug Policy. 2018 May; 55:183-186
• Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
  Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME
  J Viral Hepat. 2018 Apr; 25(9):1089-1098
• Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
  Goutzamanis S, Doyle JS, Thompson A, Dietze P, Hellard M, Higgs P; TAP study group.
  BMC Infect Dis. 2018 Apr; 18(1):151
• Undiagnosed HIV infections among gay and bisexual men increasingly contribute to new infections in Australia.
  Gray RT, Wilson DP, Guy RJ, Stoové M, Hellard ME, Prestage GP, Lea T, de Wit J, Holt M
  J Int AIDS Soc. 2018 Apr; 21(4):e25104
• Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
  Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME
  J Int AIDS Soc. 2018 Apr; 21 Suppl 2:e25051
• Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
  Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
  J Virus Erad. 2018 Apr; 4(2):108-114
• Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
  Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME
  Clin Infect Dis. 2018 Mar; 66(7):1019-1023
• Comparing Australian gay and bisexual men with undiagnosed and recently diagnosed HIV infection to those in the National HIV Registry.
  Down I, Prestage G, Brown G, Ellard J, Guy R, Hellard M, Wilson D, de Wit J, Stoové M, Holt M
  Sex Health. 2018 Mar; 15(3):276-281
• Effects of Pre-exposure Prophylaxis for the Prevention of HIV Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis.
  Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA
  Clin Infect Dis. 2018 Mar; 67(5):676-686
• Rising Chlamydia and Gonorrhoea Incidence and Associated Risk Factors Among Female Sex Workers in Australia: A Retrospective Cohort Study.
  Callander D, McManus H, Guy R, Hellard M, O'Connor CC, Fairley CK, Chow EPF, McNulty A, Lewis DA, Carmody C, Schmidt HA, Kim J, Donovan B
  Sex Transm Dis. 2018 Mar; 45(3):199-206
• A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and Australia.
  Marukutira T, Stoové M, Lockman S, Mills LA, Gaolathe T, Lebelonyane R, Jarvis JN, Kelly SL, Wilson DP, Luchters S, Crowe SM, Hellard M
  J Int AIDS Soc. 2018 Mar; 21(3):e25090
• Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
  Hellard M, Scott N, Sacks Davis R, Pedrana A
  J Hepatol. 2018 Feb; 68(3):383-385
• Declining prevalence of undiagnosed HIV in Melbourne: results from community-based bio-behavioural studies of gay and bisexual men.
  Stoové M, Asselin J, Pedrana A, Lea T, Hellard M, Wilson D, Prestage G, de Wit J, Holt M
  Aust N Z J Public Health. 2018 Feb; 42(1):57-61
• People Born In Non-Main English Speaking Countries Are Less Likely To Start Hiv Treatment Early In Australia: A National Cohort Analysis, 2014-15.
  Gunaratnam P, McManus H, Watchirs-Smith L, McGregor S, Callander D, Brown G, Lobo R, O'Connor CC, Hellard M, Medland N, Lewis D, Palmer C, Law M, Gray R, Donovan B, Guy R; ACCESS Steering Committee
  J Acquir Immune Defic Syndr. 2018 Feb; 77(3):e31-e34
• Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
  Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, Benitez Hernandez U, Sigmundsdóttir G, Hellard M
  J Hepatol. 2018 Feb; 68(5):932-939
• What Behaviors Do Young Heterosexual Australians See in Pornography? A Cross-Sectional Study.
  Davis AC, Carrotte ER, Hellard ME, Lim MSC
  J Sex Res. 2018 Jan; 55(3):310-319
• The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
  Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.
  Clin Infect Dis. 2018 Jan; 66(1):20-28
• Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
  Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group
  Lancet Gastroenterol Hepatol. 2018 Jan; 3(3):153-161
• Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
  Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M
  J Int AIDS Soc. 2018 Jan; 21(1):e25059
• Understanding the Targeting and Uptake of HIV Testing Among Gay and Bisexual Men Attending Sexual Health Clinics.
  Jamil MS, McManus H, Callander D, Prestage G, Ali H, O'Connor CC, Chen M, McNulty AM, Knight V, Duck T, Keen P, Gray J, Medland N, Hellard M, Lewis DA, Grulich AE, Kaldor JM, Fairley CK, Donovan B, Guy RJ; ACCESS and NSW Partnership Project Steering Committees.
  AIDS Behav. 2018 Jan; 22(2):513-521
• Acceptability and HIV prevention benefits of a peer-based model of rapid point of care HIV testing for Australian gay, bisexual and other men who have sex with men.
  Leitinger D, Ryan KE, Brown G, Pedrana A, Wilkinson AL, Ryan C, Hellard M, Stoové M
  AIDS Behav. 2018 Jan; 22(1):178-189
• Syndromic management of sexually transmissible infections in resource-poor settings: a systematic review with meta-analysis of the abnormal vaginal discharge flowchart for Neisseria gonorrhoea and Chlamydia trachomatis.
  van Gemert C, Hellard M, Bradshaw CS, Fowkes FJI, Agius PA, Stoove M, Bennett CM
  Sex Health. 2018 Jan; 15(1):1-12
• Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004-2014.
  van Gemert CE, Murphy N, Mitchell TA, Hellard ME, Thornton L
  Ir J Med Sci. 2018 Jan; 187(3):803-811

2017 (34)

• Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data.
  Boettiger DC, Law MG, Dore GJ, Guy R, Callander D, Donovan B, O'Connor CC, Fairley CK, Hellard M, Matthews G
  BMC Infect Dis. 2017 Dec; 17(1):740
• WHO guidelines on testing for hepatitis B and C - meeting targets for testing.
  Hellard ME, Chou R, Easterbrook P
  BMC Infect Dis. 2017 Nov; 17(Suppl 1):703
• Methodological challenges in appraising evidence on diagnostic testing for WHO guidelines on hepatitis B and hepatitis C virus infection.
  Chou R, Easterbrook P, Hellard M
  BMC Infect Dis. 2017 Nov; 17(Suppl 1):694
• Trial and error: evaluating and refining a community model of HIV testing in Australia.
  Ryan KE, Pedrana A, Leitinger D, Wilkinson AL, Locke P, Hellard ME, Stoové M
  BMC Health Serv Res. 2017 Oct; 17(1):692
• Pathways to the elimination of hepatitis C: prioritising access for all.
  Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME
  Expert Rev Clin Pharmacol. 2017 Oct; 10(10):1023-1026
• Anorectal swabs as a marker of male-to-male sexual exposure in STI surveillance systems.
  Ampt FH, El Hayek C, Agius PA, Bowring AL, Bartnik N, Van Gemert C, Fairley CK, Chow EPF, Bradshaw CS, Stephens N, Lim MSC, Hellard ME
  Epidemiol Infect. 2017 Sep; 145(12):2530-2535
• Knowledge and practices of chronic hepatitis B virus testing by general practitioners in Victoria, Australia, 2014-15.
  van Gemert C, Howell J, Wang J, Stoové M, Cowie B, Allard N, Enright C, Dunn E, Towell V, Hellard M
  Aust Fam Physician. 2017 Sep; 46(9):683-689
• Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
  Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.
  Int J Drug Policy. 2017 Sep; 47:177-186
• Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
  Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
  Int J Drug Policy. 2017 Sep; 47:107-116
• WHISPER or SHOUT study: protocol of a cluster-randomised controlled trial assessing mHealth sexual reproductive health and nutrition interventions among female sex workers in Mombasa, Kenya.
  Ampt FH, Mudogo C, Gichangi P, Lim MSC, Manguro G, Chersich M, Jaoko W, Temmerman M, Laini M, Comrie-Thomson L, Stoové M, Agius PA, Hellard M, L'Engle K, Luchters S
  BMJ Open. 2017 Aug; 7(8):e017388
• Increased syphilis testing of men who have sex with men: greater detection of asymptomatic early syphilis and relative reduction in secondary syphilis.
  Chow EPF, Callander D, Fairley CK, Zhang L, Donovan B, Guy R, Lewis DA, Hellard M, Read P, Ward A, Chen MY; ACCESS collaboration.
  Clin Infect Dis. 2017 Aug; 65(3):389-395
• Young Australians' use of pornography and associations with sexual risk behaviours.
  Lim MSC, Agius PA, Carrotte ER, Vella AM, Hellard ME
  Aust N Z J Public Health. 2017 Aug; 41(4):438-443
• New hepatitis C antiviral treatments eliminate the virus.
  Doyle JS, Thompson AJ, Higgs P, Stoove M, Dietze PM, Hellard ME
  Lancet. 2017 Jul; 390(10092):358-359
• Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
  Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users.
  Int J Drug Policy. 2017 Jul; 47:51-60
• Re-examining blood donor deferral criteria relating to injecting drug use.
  Quinn B, Seed C, Keller A, Maher L, Wilson D, Farrell M, Caris S, Williams J, Madden A, Thompson A, Pink J, Hellard ME
  Int J Drug Policy. 2017 Jun; 48:9-17
• Injecting drug use in low and middle income countries: opportunities to improve care and prevent harm.
  O'Keefe D, Stoové M, Doyle J, Dietze P, Hellard M.
  J Viral Hepat. 2017 Jun; 24(9):714-724
• Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
  Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.
  Int J Drug Policy. 2017 Jun; 47:230-238
• Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
  Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group
  BMC Infect Dis. 2017 Jun; 17(1):420
• A cross-sectional study of HIV and STIs among male sex workers attending Australian sexual health clinics.
  Callander D, Read P, Prestage G, Minichiello V, Chow EP, Lewis DA, McNulty A, Ali H, Hellard M, Guy R, Donovan B
  Sex Transm Infect. 2017 Jun; 93(4):299-302
• An ecological momentary intervention to reduce alcohol consumption in young adults delivered during drinking events: Protocol for a pilot randomized controlled trial.
  Wright CJ, Dietze PM, Agius PA, Kuntsche E, Room R, Livingston M, Hellard M, Lim MS
  JIMR Research Protocols. 2017 May; 6(5):e95
• "We Might Get Some Free Beers": Experience and Motivation for Transactional Sex Among Behaviorally Bisexual Men in Vientiane, Laos.
  Bowring AL, Pasomsouk N, Hughes C, van Gemert C, Higgs P, Sychareun V, Hellard M, Power R
  Arch Sex Behav. 2017 May; 46(4):1047-1059
• Correlates of sexually transmissible infection testing among a sample of at-risk young Australians.
  Douglass CH, Vella AM, Hellard ME, Lim MSC
  Aust J Prim Health. 2017 Apr; 23(3):272-277
• Wilkinson et al. Respond to "Latent Transition Analyses in Clinical Cohorts".
  Wilkinson AL, El-Hayek C, Fairley CK, Roth N, Tee BK, McBryde E, Hellard M, Stoové M
  Am J Epidemiol. 2017 Apr; 185(8):639-640
• Utility of risk-based chlamydia testing in primary care: analysis of retrospective surveillance data among women in Melbourne, Australia.
  Wilkinson AL, McNamee K, El-Hayek C, Chow EP, Bradshaw CS, Roth N, Tee BK, Stoové M, Hellard M
  Sex Health. 2017 Apr; 14(3):268-273
• Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 Collaboration.
  Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, Cox AL, Dore G, Grebely J, Kim AY, Lauer GM, Lloyd A, Rice T, Shoukry N, Maher L, Page K; International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3).
  Clin Infect Dis. 2017 Apr; 64(7):860-869
• A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
  Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
  Aust Fam Physician. 2017 Apr; 46(4):235-240
• Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
  Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME
  Gut. 2017 Mar; 66(8):1507-1515
• Measuring transitions in sexual risk among Men Who Have Sex With Men: The novel use of latent class and latent transition analysis in HIV sentinel surveillance.
  Wilkinson AL, El-Hayek C, Fairley CK, Roth N, Tee BK, McBryde E, Hellard M, Stoové M
  Am J Epidemiol. 2017 Mar; 185(8):627-635
• Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
  Hellard M, Pedrana A, Scott N
  J Hepatol. 2017 Feb; 66(2):270-272
• HCV reinfection incidence among individuals treated for recent infection.
  Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV
  J Viral Hepat. 2017 Feb; 24(5):359-370
• Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.
  Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC3 Study Group
  Infect Genet Evol. 2017 Jan; 49:88-96
• Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
  Eltahla AA, Rodrigo C, Betz-Stablein B, Grebely J, Applegate T, Luciani F, Schinkel J, Dore GJ, Page K, Bruneau J, Morris MD, Cox AL, Kim AY, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Lloyd AR, Bull RA; InC3 Study Group.
  J Viral Hepat. 2017 Jan; 24(1):37-42
• Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
  Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative
  J Viral Hepat. 2017 Jan; 24(1):43-52
• A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
  Bartlett SR, Wertheim JO, Bull RA, Matthews GV, Lamoury FM, Scheffler K, Hellard M, Maher L, Dore GJ, Lloyd AR, Applegate TL, Grebely J
  J Viral Hepat. 2017 Jan; 24(5):404-411

2016 (37)

• Achieving development goals for HIV, tuberculosis and malaria in sub-Saharan Africa through integrated antenatal care: barriers and challenges.
  Fowkes FJ, Draper BL, Hellard M, Stoové M
  BMC Med. 2016 Dec; 14(1):202
• A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.
  Callander D, Stoové M, Carr A, Hoy JF, Petoumenos K, Hellard M, Elliot J, Templeton DJ, Liaw S, Wilson DP, Grulich A, Cooper DA, Pedrana A, Donovan B, McMahon J, Prestage G, Holt M, Fairley CK, McKellar-Stewart N, Ruth S, Asselin J, Keen P, Cooper C, Allan B, Kaldor JM, Guy R
  BMC Infect Dis. 2016 Dec; 16(1):752
• The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males.
  Tsui JI, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore GJ, Lauer G, Lloyd AR, Page K
  Drug Alcohol Depend. 2016 Dec; 169:156-62
• Direct-acting antiviral treatment for HCV.
  Goutzamanis S, Doyle J, Thompson A, Hellard M, Higgs P
  Lancet Infect Dis. 2016 Dec; 16(12):1325-6
• Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
  Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV
  Hepatology. 2016 Dec; 64(6):1911-1921
• Lack of heterologous cross-reactivity towards HLA-A*02:01 restricted viral epitopes is underpinned by distinct alphabetaT cell receptor signatures.
  Grant EJ, Josephs TM, Valkenburg SA, Wooldridge L, Hellard M, Rossjohn J, Bharadwaj M, Kedzierska K, Gras S
  J Biol Chem. 2016 Nov; 291(47):24335-24351
• Historical trends in the hepatitis C virus epidemics in North America and Australia.
  Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; InC3 Study Group
  J Infect Dis. 2016 Nov; 214(9):1383-1389
• A nurse-led intervention improved blood-borne virus testing and vaccination in Victorian prisons.
  Winter RJ, White B, Kinner SA, Stoové M, Guy R, Hellard ME
  Aust N Z J Public Health. 2016 Oct; 40(6):592-594
• Exploring attitudes towards sexting of young people: a cross-sectional study.
  Lim MS, Vella AM, Horyniak DR, Hellard ME
  Sexual Health. 2016 Oct; 13(6):530-535
• Resumption of injecting drug use following release from prison in Australia.
  Winter RJ, Young JT, Stoové M, Agius PA, Hellard ME, Kinner SA
  Drug Alcohol Depend. 2016 Sep; 168:104-111
• Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.
  Bradshaw D, Raghwani J, Jacka B, Sacks-Davis R, Lamoury F, Down I, Prestage G, Applegate TL, Hellard M, Sasadeusz J, Dore GJ, Pybus OG, Matthews GV, Danta M
  PLoS One. 2016 Sep; 11(9):e0162002
• A 'test and treat' prevention strategy in Australia requires innovative HIV testing models: a cohort study of repeat testing among 'high-risk' men who have sex with men.
  Wilkinson AL, El-Hayek C, Spelman T, Fairley CK, Leslie D, McBryde ES, Hellard M, Stoové M
  Sex Transm Infect. 2016 Sep; 92(6):464-466
• Characteristics of gay, bisexual and other men who have sex with men testing and retesting at Australia’s first shop-front rapid point-of-care HIV testing service.
  Ryan KE, Wilkinson AL, Leitinger D, El-Hayek C, Ryan C, Pedrana A, Hellard M, Stoové M
  Sex Health. 2016 Aug; 13(6):560-567
• "I am yet to encounter any survey that actually reflects my life": a qualitative study of inclusivity in sexual health research.
  Carrotte ER, Vella AM, Bowring AL, Douglass C, Hellard ME, Lim MS
  BMC Med Res Methodol. 2016 Jul; 16(1):86
• Field engagement further facilitates hepatitis B vaccination completion: Letter in response to: Day et al. (in press).
  Higgs P, Doyle J, Luppi J, Dietze P, Hellard M
  J Clin Virol. 2016 Jul; 82:64-65
• Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
  Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, Hellard M, Beyrer C, Altice FL
  Lancet. 2016 Jul; 388(10049):1089-1102
• Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
  Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group.
  PLoS One. 2016 Jun; 11(6):e0150655
• Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.
  Hellard M, Sacks-Davis R, Doyle J
  J Epidemiol Commun Health. 2016 Jun; 70:1151-1154
• Water, Sanitation, and Hygiene Facilities and Hygiene Practices Associated with Diarrhea and Vomiting in Monastic Schools, Myanmar.
  Weaver ER, Agius PA, Veale H, Dorning K, Hlang TT, Aung PP, Fowkes FJ, Hellard ME
  Am J Trop Med Hyg. 2016 Jun; 95(2):278-287
• Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
  Chen Yi Mei SL, Burchell J, Skinner N, Millen R, Matthews G, Hellard M, Dore GJ, Desmond P, Sundararajan V, Thompson A, Visvanathan K, Sasadeusz J.
  J Infect Dis. 2016 Jun; 214(5):739-747
• HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.
  Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J and the ATAHC Study Group.
  BMC Infect Dis. 2016 Jun; 16(1):241
• The role of living context in prescription opioid injection and the associated risk of hepatitis C infection.
  Sacks-Davis R, Daniel M, Roy E, Kestens Y, Zang G, Ramos Y, Hellard M, Jutras Aswad D, Bruneau J
  Addiction. 2016 May; 111(11):1985-1996
• The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P
  PLoS One. 2016 May; 11(5):e0156213
• A systematic review of community based hepatitis C treatment.
  Wade AJ, Veronese V, Hellard ME, Doyle JS.
  BMC Infect Dis. 2016 May; 16(1):202
• Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
  Higgs P, Wright C, Hellard M
  Aliment Pharmacol Ther. 2016 Apr; 43(7):840-841
• Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.
  Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.
  Virol J. 2016 Feb; 13(1):32
• Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
  Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV
  Antivir Ther. 2016 Feb; 21(5):425-434
• Improving the identification of priority populations to increase hepatitis B testing rates, 2012.
  van Gemert C, Wang J, Simmons J, Cowie B, Boyle D, Stoove M, Enright C, Hellard M
  BMC Public Health. 2016 Feb; 16(1):95
• The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand.
  Howell J, Balderson G, Hellard M, Gow PJ, Strasser SI, Stuart KA, Wigg A, Jeffrey G, Gane E, Angus PW
  J Gastroenterol Hepatol. 2016 Feb; 31(2):434-441
• Modelling hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges.
  Scott N, Hellard M, McBryde E
  Virulence. 2016 Feb; 7(2):201-208
• Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
  Scott N, Iser D, Thompson A, Doyle J, Hellard M
  J Gastroenterol Hepatol. 2016 Feb; 31(4):872-882
• HIV and Sexual Risk Among Men Who Have Sex With Men and Women in Asia: A Systematic Review and Meta-Analysis.
  Bowring AL, Veronese V, Doyle JS, Stoové M, Hellard M
  AIDS Behav. 2016 Jan; 20(10):2243-2265
• Mental Health and Associated Sexual Health Behaviours in a Sample of Young People Attending a Music Festival in Melbourne, Victoria.
  Carrotte ER, Vella AM, Hellard ME, Lim MS
  Community Ment Health J. 2016 Jan; 52(8):1082-1088
• The impact of pornography on gender-based violence, sexual health and well-being: what do we know?
  Lim MS, Carrotte ER, Hellard ME
  J Epidemiol Community Health. 2016 Jan; 70(1):3-5
• Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.
  Page K, Mirzazadeh A, Rice TM, Grebely J, Kim AY, Cox AL, Morris MD, Hellard M, Bruneau J, Shoukry NH, Dore GJ, Maher L, Lloyd AR, Lauer G, Prins M, McGovern BH
  Open Forum Infect Dis. 2016 Jan; 3(1):ofw024
• HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.
  Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd A, Grebely J, Applegate T
  Infect Genet Evol. 2016 Jan; 37:252-258
• The Impact of a Social Marketing Campaign on HIV and Sexually Transmissible Infection Testing Among Men Who Have Sex With Men in Australia.
  Wilkinson AL, Pedrana AE, El-Hayek C, Vella AM, Asselin J, Batrouney C, Fairley CK, Read TR, Hellard M, Stoové M
  Sex Transm Dis. 2016 Jan; 43(1):49-56

2015 (31)

• Sex and Sport: An Australian Rules Football-Based Chlamydia Screening Initiative (Book Chapter)
  Kong FYS, Hellard M, Hocking J
  in "Sport-Based Health Interventions" Ed David Conrad and Helen White (Springer). 2015 Dec; Chapter 11:151-159
• The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
  Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME
  PLoS One. 2015 Nov; 10(11):e0142770
• The prevalence and correlates of undiagnosed HIV among Australian gay and bisexual men: results of a national, community-based, bio-behavioural survey.
  Holt M, Lea T, Asselin J, Hellard M, Prestage G, Wilson D, de Wit J, Stoové M
  J Int AIDS Soc. 2015 Nov; 18(1):20526
• Behavioural research to inform understanding of hepatitis C resistance.
  Higgs P, Dwyer R, Cogger S, Hellard M, Maher L
  Lancet Infect Dis. 2015 Nov; 15(11):1260-1261
• Factors Influencing Access to Sexual Health Care Among Behaviorally Bisexual Men in Vientiane, Laos: A Qualitative Exploration.
  Bowring AL, Pasomsouk N, Higgs P, Sychareun V, Hellard M, Power R
  Asia Pac J Public Health. 2015 Nov; 27(8):820-834
• Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics.
  Ragonnet R, Trauer JM, Denholm JT, Geard NL, Hellard M, McBryde ES
  Sci Rep. 2015 Oct; 5:15468
• The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
  Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M
  BMC Med. 2015 Aug; 13:198
• Recommendations for the management of hepatitis C virus infection among people who inject drugs.
  Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users.
  Int J Drug Policy. 2015 Jul; 26(10):1028-1038
• It goes both ways: a cross-sectional study of buying and selling sex among young behaviourally bisexual men in Vientiane, Laos.
  Bowring AL, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M.
  Sex Health. 2015 Jul; 12(5):405-10
• Overview of viral hepatitis treatment research in China. (WHO Report)
  El-Hayek C, Zou H, Hua B, Cheah S, Majumdar S, Hellard M
  WHO China. 2015 Jul
• Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
  Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ and the InC3 Study Group.
  J Viral Hepat. 2015 Jun; 22(12):1020-1023
• Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia.
  Winter RJ, Stoové M, Degenhardt L, Hellard ME, Spelman T, Jenkinson R, McCarthy DR, Kinner SA
  Drug Alcohol Depend. 2015 Jun; 153:43-49
• The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
  Hellard M, Scott N
  Addiction. 2015 Jun; 110(6):984-985
• Global policy and access to new hepatitis C therapies for people who inject drugs
  Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME
  Int J Drug Policy. 2015 Jun; 26(11):1064-1071
• Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
  Alavi M, Spelman T, Matthews GV, Haber PS, Day C, van Beek I, Walsh N, Yeung B, Bruneau J, Petoumenos K, Dolan K, Kaldor JM, Dore GJ, Hellard M, Grebely J; ATAHC Study Group
  Int J Drug Policy. 2015 May; 26(10):976-983
• Hepatitis C transmission and treatment as prevention - The role of the injecting network.
  Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G
  Int J Drug Policy. 2015 May; 26(10):958-962
• How "Hidden" Are Unobserved Networks Among People Who Inject Drugs?
  Higgs P, Sacks-Davis R, Aitken C, Hellard M
  Am J Public Health. 2015 Apr; 105(6):e3
• Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study.
  Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M; InC3 study group
  J Infect Dis. 2015 Apr; 212(9):1407-19
• Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study.
  Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J; InC3 Study Group
  PLoS One. 2015 Apr; 10(4):e0122232
• "Seek, Test, Treat" Lessons from Australia: A Study of HIV testing patterns from a cohort of men who have sex with men.
  Wilkinson AL, El-Hayek C, Spelman T, Fairley C, Leslie D, McBryde E, Hellard M, Stoové M
  J Acquir Immune Defic Syndr. 2015 Mar; 69(4):460-465
• A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.
  Spelman T, Morris MD, Zang G, Rice T, Page K, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry NH, Hellard M, Bruneau J; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3 Study).
  J Epidemiol Community Health. 2015 Mar; 69(8):745-752
• Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.
  Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P
  J R Soc Interface. 2015 Mar; 12(104)
• Increased testing for Neisseria gonorrhoeae with duplex nucleic acid amplification tests in Australia: implications for surveillance.
  Donovan B, Dimech W, Ali H, Guy R, Hellard M
  Sex Health. 2015 Feb; 12(1):48-50
• The use of social networking platforms for sexual health promotion: identifying key strategies for successful user engagement.
  Veale HJ, Sacks-Davis R, Weaver ERN, Pedrana AE, Stoové MA, Hellard ME
  BMC Public Health. 2015 Feb; 15(1):85
• Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
  Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoové M, Wiktor SZ, Hutchinson S
  Eur J Epidemiol. 2015 Feb; 30(2):115-129
• Sexual identity, same-sex partners and risk behaviour among a community-based sample of young people in Australia.
  Bowring AL, Vella AM, Degenhardt L, Hellard M, Lim MS
  Int J Drug Policy. 2015 Feb; 26(2):153-161
• Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC study.
  Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; the InC3 Study Group.
  J Viral Hepat. 2015 Jan; 22(9):708-717
• 'Ice epidemic'? Trends in methamphetamine use from three Victorian surveillance systems.
  Lim MS, Cogger S, Quinn B, Hellard ME, Dietze PM
  Aust N Z J Public Health. 2015 Jan; 39(2):194-195
• Young people's comparative recognition and recall of an Australian Government Sexual Health Campaign.
  Lim MS, Gold J, Bowring AL, Pedrana AE, Hellard ME
  Int J STD AIDS. 2015 Jan; 26(6):398-401
• Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
  Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV
  Antivir Ther. 2015 Jan; 20(2):199-208
• A reality check for aspirational targets to end HIV.
  Wilson DP, Stoové MA, Hellard M
  Lancet HIV. 2015 Jan; 2(1):e11

2014 (30)

• Young risk takers: Alcohol, illicit drugs, and sexual practices among a sample of music festival attendees.
  Jenkinson R, Bowring A, Dietze P, Hellard M, Lim MSC
  J Sex Trans Dis. 2014 Dec; 2014:e357239
• Setting the scene: locations for meeting sex partners among behaviorally bisexual men in vientiane, laos, and opportunities for health promotion.
  Bowring AL, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Agius PA, Toole M, Hellard M
  AIDS Educ Prev. 2014 Dec; 26(6):538-553
• The medium and the message: fitting sound health promotion methodology into 160 characters.
  Lim MS, Wright C, Hellard ME
  JMIR Mhealth Uhealth. 2014 Nov; 2(4):e40
• An extensive antigenic footprint underpins immunodominant TCR adaptability against a hypervariable viral determinant.
  Nivarthi UK, Gras S, Kjer-Nielsen L, Berry R, Lucet IS, Miles JJ, Tracy SL, Purcell AW, Bowden DS, Hellard M, Rossjohn J, McCluskey J, Bharadwaj M
  J Immunol. 2014 Oct; 193(11):5402-5413
• Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC Study.
  Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC(3)Study Group.
  J Clin Virol. 2014 Sep; 61(3):430-434
• Early age at first sex: associations with sexual health and sociodemographic factors among a sample of young music festival attendees in Melbourne.
  Vella AM, Agius PA, Bowring AL, Hellard ME, Lim MS
  Sex Health. 2014 Aug; 11(4):359-365
• The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.
  Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, McBryde E
  Hepatology. 2014 Aug; 60(6):1861-1870
• A Comparison of Risk Factors for Hepatitis C Among Young and Older Adult Prisoners.
  van Dooren K, Kinner SA, Hellard M
  J Correct Health Care. 2014 Aug; 20(4):280-291
• Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.
  White B, Madden A, Prins M, Hellard M, Wand H, Dore GJ, Page K, Maher L
  Vaccine. 2014 Aug; 32(42):5460-5467
• An overview of hepatitis B prevalence, prevention and management in the pacific islands and territories.
  Howell J, Van Gemert C, Lemoine M, Thursz M, Hellard M
  J Gastroent Hepatol. 2014 Aug; 29(11):1854-1866
• Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a systematic review and meta-analysis.
  Doyle JS, Degenhardt L, Pedrana AE, McBryde ES, Guy R, Stoové MA, Weaver E, Grulich AE, Lo YR, Hellard M
  Clin Infect Dis. 2014 Aug; 59(10):1483-1494
• Reattendance and chlamydia retesting rates at 12 months among young people attending Australian general practice clinics 2007-10: a longitudinal study.
  Weaver ER, Bowring AL, Guy R, van Gemert C, Hocking JS, Boyle DI, Merritt T, Heal C, Lau PM, Donovan B, Hellard ME
  Sex Health. 2014 Jul; 11(4):366-369
• Dynamics of HCV RNA levels during acute hepatitis C virus infection.
  Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ (on behalf of the ATAHC study group)
  J Med Virol. 2014 Jul; 86(10):1722-1729
• Prevalence, correlates, and attitudes towards sexting among young people in Melbourne, Australia
  Yeung T, Horyniak D, Vella A, Hellard M, Lim M
  Sex Healtrh. 2014 Jul; 11(4):332-339
• Chlamydia among Australian Aboriginal and/or Torres Strait Islander people attending sexual health services, general practices and Aboriginal community controlled health services.
  Ward J, Goller J, Ali H, Bowring A, Couzos S, Saunders M, Yau P, Kaldor JM, Hellard M, Guy RJ, Donovan B
  BMC Health Serv Res. 2014 Jul; 14(1):285
• A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.
  Hall K, Sacks-Davis R, Doyle J, Aspinall E, Hutchinson S, Hellard M
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2014 Jul
• Analysis of laboratory testing results collected in an enhanced chlamydia surveillance system in Australia, 2008-2010.
  Dimech W, Lim MS, Van Gemert C, Guy R, Boyle D, Donovan B, Hellard M
  BMC Infect Dis. 2014 Jun; 14(1):325
• High chlamydia positivity rates in Indigenous people attending Australian sexual health services.
  O'Connor CC, Ali H, Guy RJ, Templeton DJ, Fairley CK, Chen MY, Dickson BM, Marshall LJ, Grulich AE, Hellard ME, Kaldor JM, Donovan B, Ward JS
  Med J Aust. 2014 Jun; 200(10):595-598
• Moving towards HIV treatment as prevention.
  Stoové MA, Pedrana AE, Hellard ME
  Microbiol Aust. 2014 May; 35(2):88-90
• No Drama: Key Elements to the Success of an HIV/STI-Prevention Mass-Media Campaign.
  Pedrana AE, Hellard ME, Higgs P, Asselin J, Batrouney C, Stoové M
  Qual Health Res. 2014 Apr; 24(5):695-705
• Urbanisation and sexual health: Understanding bisexually active men in Hanoi, Vietnam.
  Higgs P, Reddel S, Pham HV, Khoat VD, Hellard M
  Health Psychol Behav Med. 2014 Apr; 2(1):613-622
• Identifying risk: a comparison of risk between heterosexual-identifying bisexual men and other bisexual men in vientiane, laos.
  Bowring A, van Gemert C, Vongsaiya K, Hughes C, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M
  AIDS Educ Prev. 2014 Apr; 26(2):109-121
• Young people's comfort receiving sexual health information via social media and other sources.
  Lim MS, Vella A, Sacks-Davis R, Hellard ME
  Int J STD AIDS. 2014 Mar; 25(14):1003-1008
• Trends in chlamydia positivity among heterosexual patients from the Victorian Primary Care Network for Sentinel Surveillance, 2007-2011.
  Lim MS, El-Hayek C, Goller JL, Fairley CK, Nguyen PL, Hamilton RA, Henning DJ, McNamee KM, Hellard ME, Stoove MA
  Med J Aust. 2014 Feb; 200(3):166-169
• Eradication of hepatitis C infection: The importance of targeting people who inject drugs.
  Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E
  Hepatology. 2014 Jan; 59(2):366-369
• Interferon-free hepatitis C treatment: one pill to fit all?
  Hellard ME, Doyle J
  Lancet. 2014 Jan; 383(9916):491-492
• Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study.
  Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, Hellard ME
  Int J Drug Policy. 2014 Jan; 25(1):179-182
• Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
  Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ
  Int J Epidemiol. 2014 Jan; 43(1):235-248
• Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.
  Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M
  Hepat Mon. 2014 Jan; 14(1):e14678
• The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection.
  Grebely J, Page K, Sacks-Davis R, Schim van der Loeff M, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; the InC3 Study Group
  Hepatology. 2014 Jan; 59(1):109-20

2013 (34)

• Acquisition of HIV by African-Born Residents of Victoria, Australia: Insights from Molecular Epidemiology.
  Lemoh C, Ryan CE, Sekawi Z, Hearps AC, Aleksic E, Chibo D, Grierson J, Baho S, Street A, Hellard M, Biggs BA, Crowe SM
  PLoS One. 2013 Dec; 8(12):e84008
• Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.
  Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, McGovern BH, Shoukry NH, Lauer G, Maher L, Lloyd AR, Hellard M, Prins M, Dore GJ, Page K; on behalf of the InC Study Group
  Int J Epidemiol. 2013 Dec; 42(6):1649-1659
• Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection.
  Feld JJ, Grebely J, Matthews GV, Applegate T, Hellard M, Sherker A, Cherepanov V, Petoumenos K, Yeung B, Kaldor JM, Lloyd AR, Dore GJ
  PLoS One. 2013 Nov; 8(11):e80003
• High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study.
  Sacks-Davis R, Aitken CK, Higgs P, Spelman T, Pedrana AE, Bowden S, Bharadwaj M, Nivarthi UK, Suppiah V, George J, Grebely J, Drummer HE, Hellard M
  PLoS One. 2013 Nov; 8(11):e80216
• Hepatitis C transmission and treatment in contact networks of people who inject drugs.
  Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, Robins G, Hellard M
  PLoS One. 2013 Nov; 8(11):e78286
• Increasing access by priority populations to Australian sexual health clinics.
  Ali H, Donovan B, Fairley CK, Chen MY, O'Connor CC, Grulich AE, McNulty A, Ryder N, Hellard ME, Guy RJ; ACCESS Collaboration."
  Sex Transm Dis. 2013 Oct; 40(10):819-821
• Quantifying current hepatitis C virus incidence in Egypt - Response to letter by Miller and Abu-Raddad.
  Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK
  J Viral Hepat. 2013 Sep; 20(9):668
• Are Australian sexual health clinics attracting priority populations?
  Ali H, Donovan B, Fairley CK, Ryder N, McNulty A, Chen MY, Marshall L, O'Connor CC, Dickson B, Grulich AE, Hellard ME, Kaldor JM, Guy RJ
  Sex Health. 2013 Aug; 10:456-459
• Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis.
  Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME
  Clin Infect Dis. 2013 Aug; 57 Suppl 2:S80-S89
• Direct acting antiviral therapy versus pegylated interferon and ribavirin treatment for chronic hepatitis C infection: a meta-analytical systematic review.
  Doyle JS, Thompson AJ, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme. 2013 Jul
• A systematic review of the effectiveness of antiviral treatment compared with no treatment for chronic HCV.
  Doyle JS, Malandkar S, Aspinall EJ, Hall K, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• A systematic review and meta-analysis of targeted HCV antibody testing interventions.
  Aspinall EJ, Doyle JS, Corson S, Hunt D, Hellard ME, Hutchinson SJ
  Technical Report for World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• A systematic review of interventions to reduce alcohol consumption among individuals with chronic HCV infection.
  Hunt D, Doyle JS, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• Pegylated interferon plus ribavirin versus standard interferon plus ribavirin for chronic hepatitis C infection: a meta-analytical systematic review.
  Quinn B, Doyle JS, Howell J, Chow SM, Aspinall EJ, Hutchinson SJ, Hellard ME
  Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
• Introduction of a sexual health practice nurse is associated with increased STI testing of men who have sex with men in primary care.
  Snow AF, Vodstrcil LA, Fairley CK, El-Hayek C, Cummings R, Owen L, Roth N, Hellard ME, Chen MY
  BMC Infect Dis. 2013 Jul; 13(1):298
• Characteristics of a Sexual Network of Behaviorally Bisexual Men in Vientiane, Lao PDR, 2010.
  van Gemert C, Vongsaiya K, Hughes C, Jenkinson R, Bowring AL, Sihavong A, Phimphachanh C, Chanlivong N, Toole M, Hellard M
  AIDS Educ Prev. 2013 Jun; 25(3):232-243
• Maintenance of Th1 HCV-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
  Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.
  J Gastroenterol Hepatol. 2013 May; 28(11):1170-1781
• Preventing hepatitis C virus transmission among young people in the justice system.
  Lenton E, White B, Aitken C, Hellard M, Higgs P
  Children Youth Serv Rev. 2013 May; 35(5):834-6
• Sexual Health Promotion on Social Networking Sites: A Process Evaluation of the FaceSpace Project.
  Nguyen P, Gold J, Pedrana A, Chang S, Howard S, Ilic O, Hellard M, Stoové M
  J Adolesc Health. 2013 Apr; 53(1):98-104
• Comparing short versions of the AUDIT in a community-based survey of young people.
  Bowring AL, Gouillou M, Hellard M, Dietze P
  BMC Public Health. 2013 Apr; 13(1):301
• Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?
  Feigin A, El-Hayek C, Hellard M, Pedrana A, Donnan E, Fairley C, Tee BK, Stoové M
  Sex Health. 2013 Apr; 10(2):166-170
• Modelling a disease-relevant contact network of people who inject drugs
  Rolls DA, Wang P, Jenkinson R, Pattison PE, Robins GL, Sacks-Davis R, Daraganova G, Hellard M, McBryde E
  Soc Net. 2013 Apr; 35(4):699-710
• Towards realistic estimates of HCV incidence in Egypt
  Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK
  J Viral Hepat. 2013 Mar; 20(4):294-296
• HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
  Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M
  Hepatology. 2013 Mar; 58(5):1598-1609
• Current and emerging antiviral treatments for hepatitis C infection.
  Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME
  Br J Clin Pharmacol. 2013 Mar; 75(4):931-43
• Queer as F**k: Reaching and Engaging Gay Men in Sexual Health Promotion through Social Networking Sites.
  Pedrana A, Hellard M, Gold J, Ata N, Chang S, Howard S, Asselin J, Ilic O, Batrouney C, Stoové M
  J Med Internet Res. 2013 Feb; 15(2):e25
• The spread of influenza A(H1N1)pdm09 in Victorian school children in 2009: implications for revised pandemic planning
  Fielding JE, Bergeri I, Higgins N, Kelly HA, Meagher J, McBryde ES, Moran R, Hellard ME, Lester RA
  PLoS ONE. 2013 Feb; 8(2-3):e57265
• Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.
  Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, Zang G, Shaw I, Yeung B, George J, Teutsch S, Kaldor JM, Cherepanov V, Bruneau J, Shoukry NH, Lloyd AR, Dore GJ
  Hepatology. 2013 Jan; 57(6):2124-2134
• Increasing chlamydia test of re-infection rates using SMS reminders and incentives.
  Downing SG, Cashman C, McNamee H, Penney D, Russell DB, Hellard ME
  Sex Transm Infect. 2013 Jan; 89(1):16-19
• Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
  Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME
  J Gastroenterol Hepatol. 2013 Jan; 28(4):707-16
• Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs.
  White B, Madden A, Hellard M, Kerr T, Prins M, Page K, Dore GJ, Maher L
  Drug Alcohol Rev. 2013 Jan; 32(4):419-425
• Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: What has been the impact of targeted free vaccination?
  Winter RJ, Dietze PM, Gouillou M, Hellard ME, Robinson P, Aitken CK
  J Gastroenterol Hepatol. 2013 Jan; 28(2):314-322
• Chlamydia testing and retesting patterns at family planning clinics in Australia.
  Bowring AL, Goller JL, Gouillou M, Harvey C, Bateson D, McNamee K, Read C, Boyle D, Jordan L, Wardle R, Stephens A, Donovan B, Guy R, Hellard M
  Sex Health. 2013 Jan; 10(1):74-81
• Is rectal gonorrhoea a lead indicator of HIV transmission among men who have sex with men in Victoria, Australia?
  Wilkinson AL, Lim MS, Stoové M, Fairley CK, Chen M, El-Hayek C, Denham I, Hellard M
  Sex Health. 2013 Jan; 10(2):188-189

2012 (29)

• Chlamydia sentinel surveillance in Aboriginal Community Controlled Health Services finds higher testing and positivity rates among younger people.
  Goller JL, Ward J, Saunders M, Couzos S, Kaldor J, Hellard M
  Aust N Z J Public Health. 2012 Dec; 36(6):577-581
• Measuring the accuracy of self-reported height and weight in a community-based sample of young people.
  Bowring AL, Peeters A, Freak-Poli R, Lim MS, Gouillou M, Hellard M
  BMC Med Res Methodol. 2012 Nov; 12(1):175
• Trends in sexual behavior, testing, and knowledge in young people; 2006-2011.
  Lim MS, Bowring AL, Gold J, Aitken CK, Hellard ME
  Sex Transm Dis. 2012 Nov; 39(11):831-834
• Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs.
  Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M
  PLoS One. 2012 Oct; 7(10):e47335
• Impaired HCV-specific IFN-gamma responses in individuals with HIV who acquire HCV infection correlate with levels of CD4 cells.
  Flynn JK, Dore GJ, Matthews G, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; on behalf of the ATAHC Study Group.
  J Infect Dis. 2012 Sep; 206(10):1568-1576
• Stop the Drama Downunder: A Social Marketing Campaign Increases HIV/Sexually Transmitted Infection Knowledge and Testing in Australian Gay Men.
  Pedrana A, Hellard M, Guy R, El-Hayek C, Gouillou M, Asselin J, Batrouney C, Nguyen P, Stoovè M
  Sex Transm Dis. 2012 Aug; 39(8):651-658
• The role of viral and host genetics in natural history and treatment of chronic HCV infection.
  Doyle JS, Hellard ME, Thompson AJ
  Best Pract Res Clin Gastroenterol. 2012 Aug; 26(4):413-427
• Public-Private Partnerships for Health Promotion: The Experiences of the S5 Project.
  Gold J, Hellard ME, Lim MS, Dixon H, Wakefield M, Aitken CK.
  Amer J Health Educat. 2012 Aug; 43(4):250-53
• Correlates of Chlamydia trachomatis infection in a primary care sentinel surveillance network.
  Lim MS, Goller JL, Guy R, Gold J, Stoové M, Hocking JS, Fairley CK, Henning D, McNamee K, Owen L, Sheehan P, Hellard ME
  Sex Health. 2012 Jul; 9(3):247-253
• Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
  Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK
  Med J Aust. 2012 Jun; 196(10):638-641
• Identifying newly acquired cases of hepatitis C using surveillance: a literature review.
  Sacks-Davis R, Van Gemert C, Bergeri I, Stoové M, Hellard M
  Epidemiol Infect. 2012 Jun; 140(11):1925-1934
• Understanding trends in genital Chlamydia trachomatis can benefit from enhanced surveillance: findings from Australia.
  Ali H, Guy RJ, Fairley CK, Wand H, Chen MY, Dickson B, O'Connor CC, Marshall L, Grulich AE, Kaldor JM, Hellard ME, Donovan B; on behalf of the ACCESS Collaboration.
  Sex Transm Infect. 2012 May; 88(7):552-557
• Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection.
  Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV
  AIDS. 2012 May; 26(13):1653-1661
• The impact of khat use on East African communities in Melbourne: A preliminary investigation.
  Feigin A, Higgs P, Hellard M, Dietze P
  Drug Alcohol Rev. 2012 May; 31(3):288-293
• Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review.
  Sacks-Davis R, Horyniak D, Grebely J, Hellard M
  Int J Drug Policy. 2012 May; 23(3):176-184
• The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.
  Vickerman P, Grebely J, Dore GJ, Sacks-Davis R., Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M
  J Infect Dis. 2012 May; 205(9):1342-1350
• Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.
  Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ; on behalf of the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC(3))
  Lancet Infect Dis. 2012 May; 12(5):408-414
• Prevalence survey of dermatological conditions in mountainous north India.
  Grills N, Grills C, Spelman T, Stoové M, Hellard M, El-Hayek C, Singh R
  Int J Dermatol. 2012 May; 51(5):579-587
• Impact of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection.
  Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M, Dore GJ, Haber PS; on behalf of the ATAHC Study Group
  J Gastroenterol Hepatol. 2012 May; 27(5):957-965
• Non-cirrhotic portal hypertension in HIV mono-infected patients.
  Jackson BD, Doyle JS, Hoy JF, Roberts SK, Colman J, Hellard ME, Sasadeusz JJ, Iser DM
  J Gastroenterol Hepatol. 2012 Apr; 27(9):1512-1519
• Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
  Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M, Dore GJ, White PA; On behalf of the ATAHC Study Group.
  Hepatology. 2012 Apr; 55(4):1058-1069
• Modelling hepatitis C transmission over a social network of injecting drug users.
  Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, Pattison PE, Robins GL
  J Theor Biol. 2012 Mar; 297:73-87
• Missed opportunities--low levels of chlamydia retesting at Australian general practices, 2008-2009.
  Bowring AL, Gouillou M, Guy R, Kong FY, Hocking J, Pirotta M, Heal C, Brett T, Donovan B, Hellard M; on behalf of the ACCESS Collaboration.
  Sex Transm Infect. 2012 Mar; 88(5):330-334
• Know your limits: Awareness of the 2009 Australian alcohol guidelines among young people.
  Bowring AL, Gold J, Dietze P, Gouillou M, Van Gemert C, Hellard ME
  Drug Alcohol Rev. 2012 Mar; 31(2):213-223
• Developing health promotion interventions on social networking sites: recommendations from The FaceSpace Project.
  Gold J, Pedrana AE, Stoové MA, Chang S, Howard S, Asselin J, Ilic O, Batrouney C, Hellard ME
  J Med Internet Res. 2012 Feb; 14(1):e30
• Incidence and risk factors associated with chlamydia in men who have sex with men: a cohort analysis of Victorian Primary Care Network for Sentinel Surveillance data.
  Wilkinson A, El-Hayek C, Fairley CK, Leslie D, Roth N, Tee BK, Hellard ME, Stoové M
  Sex Transm Infect. 2012 Feb; 88(5):319-324
• High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia.
  Pedrana AE, Hellard ME, Wilson K, Guy R, Stoové M
  JAIDS. 2012 Jan; 59(1):94-99
• Impact of text and email messaging on the sexual health of young people: a randomised controlled trial.
  Lim MS, Hocking JS, Aitken CK, Fairley CK, Jordan L, Lewis JA, Hellard ME
  J Epidemiol Community Health. 2012 Jan; 66(1):69-74
• The difference in self-reported and biological measured HIV prevalence: Implications for HIV prevention.
  Pedrana AE, Hellard ME, Guy R, Wilson K, Stoové M
  AIDS Behav. 2012 Jan; 16(6):1454-1463

2011 (22)

• Exploring the sexual networks of men who have sex with men and women in Hanoi, Vietnam - Summary Report
  Siobhan Reddel, Pham Hanh Van, Nguyen Van Thuy, Peter Higgs, Khoat Van Dang, Rebecca Jenkinson, Caroline Van Gemert, Chad Hughes, Margaret Hellard, Mike Toole AM
• Exploring the sexual networks of men who have sex with men and women in Hanoi, Vietnam - Final Report
  Siobhan Reddel, Pham Hanh Van, Nguyen Van Thuy, Peter Higgs, Khoat Van Dang, Rebecca Jenkinson, Caroline Van Gemert, Chad Hughes, Margaret Hellard, Mike Toole
• Heroin and other opioids
  Dietze P, Degenhardt L, Kinner S, Hellard M, King T
  Prevention Research Quarterly. 2011 Sep; 16:1-12
• Sexual history taking and sexually transmissible infection screening practices among men who have sex with men: a survey of Victorian general practitioners.
  Barber B, Hellard M, Jenkinson R, Spelman T, Stoové M
  Sex Health. 2011 Sep; 8(3):349-354
• Risk factors for HIV seroconversion in men who have sex with men in Victoria, Australia: results from a sentinel surveillance system.
  Guy RJ, Spelman T, Stoové M, El-Hayek C, Goller J, Fairley CK, Leslie D, Tee B, Roth N, Grulich AE, Hellard ME
  Sex Health. 2011 Sep; 8(3):319-329
• Intrahousehold transmission of pandemic (H1N1) 2009 virus, Victoria, Australia.
  van Gemert C, Hellard M, McBryde ES, Fielding J, Spelman T, Higgins N, Lester R, Vally H, Bergeri I
  Emerg Infect Dis. 2011 Sep; 17(9):1599-1607
• The relationship between personality disorders and mental health, substance use severity and quality of life among injecting drug users.
  Gibbie TM, Hides LM, Cotton SM, Lubman DI, Aitken C, Hellard M
  Med J Aust. 2011 Aug; 195(3):S16-S21
• Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.
  Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA
  J Viral Hepat. 2011 Aug; 18(8):549-561
• A systematic examination of the use of Online social networking sites for sexual health promotion.
  Gold J, Pedrana AE, Sacks-Davis R, Hellard ME, Chang S, Howard S, Keogh L, Hocking JS, Stoové MA
  BMC Public Health. 2011 Jul; 11:583
• Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
  Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, Alavi M, Yeung, B, Haber PS, Lloyd, AR, Kaldor JM, Dore GJ
  J Hepatol. 2011 Jul; 55(1):76-85
• Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.
  Higgs P, Sacks-Davis R, Gold J, Hellard M
  Hepat Mon. 2011 Jul; 11(7):513-518
• The Australian national binge drinking campaign: campaign recognition among young people at a music festival who report risky drinking.
  van Gemert C, Dietze P, Gold J, Sacks-Davis R, Stoové M, Vally H, Hellard M
  BMC Public Health. 2011 Jun; 11:482
• Impact evaluation of a youth sexually transmissible infection awareness campaign using routinely collected data sources.
  Gold J, Goller J, Hellard M, Lim MS, Hocking J, Fairley CK, Spelman T, McNamee K, Clift P, Guy R
  Sex Health. 2011 Jun; 8(2):234-241
• Re-testing for chlamydia at sexual health services in Australia, 2004-08.
  Guy R, Wand H, Franklin N, Fairley CK, Chen MY, O'Connor CC, Marshall L, Grulich AE, Kaldor JM, Hellard M, Donovan B On Behalf Of The Access Collaboration
  Sex Health. 2011 Jun; 8(2):242-247
• Exploring the sexual networks of men who have sex with men and women in Lao PDR - Summary Report
  Chad Hughes, Caroline van Gemert, Kongchay Vongsaiya, Rebecca Jenkinson, Amphoy Sihavong, Chansy Phimphachanh, Niramonh Chanlivong, Margaret Hellard, Mike Toole
• Exploring the sexual networks of men who have sex with men and women in Lao PDR - Final Report
  Chad Hughes, Caroline van Gemert, Kongchay Vongsaiya, Rebecca Jenkinson, Amphoy Sihavong, Chansy Phimphachanh, Niramonh Chanlivong, Margaret Hellard, Mike Toole
• Determining the impact of text messaging for sexual health promotion to young people.
  Gold J, Lim MS, Hocking JS, Keogh LA, Spelman T, Hellard ME
  Sex Transm Dis. 2011 Apr; 38(4):247-252
• A randomised controlled trial using mobile advertising to promote safer sex and sun safety to young people.
  Gold J, Aitken CK, Dixon HG, Lim MS, Gouillou M, Spelman T, Wakefield M, Hellard ME
  Health Educ Res. 2011 Mar
• Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.
  Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, Marks P, van Beek I, Rawlinson W, Kaldor JM, Lloyd A, Dore GJ, White PA; on behalf of the ATAHC Study Group
  Clin Infect Dis. 2011 Mar; 52(6):803-811
• Australian general practitioner chlamydia testing rates among young people.
  Kong FY, Guy RJ, Hocking JS, Merritt T, Pirotta M, Heal C, Bergeri I, Donovan B, Hellard ME
  Med J Aust. 2011 Mar; 194(5):249-252
• What's your "porn star" name? A novel method of identifying research participants.
  Lim MS, Bowring A, Gold J, Hellard ME
  Sex Transm Dis. 2011 Feb; 38(2):150-151
• Antigen-driven patterns of TCR bias are shared across diverse outcomes of human hepatitis C virus infection.
  Miles JJ, Thammanichanond D, Moneer S, Nivarthi UK, Kjer-Nielsen L, Tracy SL, Aitken CK, Brennan RM, Zeng W, Marquart L, Jackson D, Burrows SR, Bowden DS, Torresi J, Hellard M, Rossjohn J, McCluskey J, Bharadwaj M
  J Immunol. 2011 Jan; 186(2):901-912

2010 (18)

• What's in a message? Delivering sexual health promotion to young people in Australia via text messaging.
  Gold J, Lim MS, Hellard ME, Hocking JS, Keogh LA
  BMC Public Health. 2010 Dec; 10:792
• The changing age distribution of men who have sex with men diagnosed with HIV in Victoria.
  El-Hayek C, Bergeri I, Hellard ME, Pedrana AE, Higgins N, Breschkin A, Stoové M
  Med J Aust. 2010 Dec; 193(11-12):655-658
• Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings.
  Goller JL, Guy RJ, Gold J, Lim MS, El-Hayek C, Stoové MA, Bergeri I, Fairley CK, Leslie DE, Clift P, White B, Hellard ME
  Sex Health. 2010 Dec; 7(4):425-433
• Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.
  Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K
  Vaccine. 2010 Oct; 28(45):7273-7278
• Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
  Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ; for the ATAHC Study Group.
  Hepatology. 2010 Oct; 52(4):1216-1224
• Randomised controlled trial of paper, online and SMS diaries for collecting sexual behaviour information from young people.
  Lim MS, Sacks-Davis R, Aitken CK, Hocking JS, Hellard ME
  J Epidemiol Community Health. 2010 Oct; 64(10):885-889
• Does the frequency of HIV and STI testing among men who have sex with men in primary care adhere with Australian guidelines?
  Guy R, Goller JL, Spelman T, El-Hayek C, Gold J, Lim M, Leslie D, Tee BK, Roth N, Anderson J, Fairley CK, Kaldor J, Hellard M
  Sex Transm Infect. 2010 Oct; 86(5):371-376
• A new national Chlamydia Sentinel Surveillance System in Australia: evaluation of the first stage of implementation.
  Guy RJ, Kong F, Goller J, Franklin N, Bergeri I, Dimech W, Reilly N, Sullivan E, Ward J, Kaldor JM, Hellard M, Donovan B; ACCESS Collaboration
  Commun Dis Intell. 2010 Sep; 34(3):319-328
• Home-based chlamydia testing of young people attending a music festival--who will pee and post?
  Sacks-Davis R, Gold J, Aitken CK, Hellard ME
  BMC Public Health. 2010 Jun; 10:376
• Further research required to determine link between khat consumption and driver impairment.
  Feigin A, Higgs P, Hellard M, Dietze P
  Bull World Health Organ. 2010 Jun; 88(6):480
• Sex and sport: sexual risk behaviour in young people in rural and regional Victoria.
  Kong FY, Hocking JS, Link CK, Chen MY, Hellard ME
  Sex Health. 2010 Jun; 7(2):205-211
• African Australians living with HIV: a case series from Victoria.
  Lemoh CN, Baho S, Grierson J, Hellard M, Street A, Biggs BA
  Sex Health. 2010 Jun; 7(2):142-148
• The utility of voluntary counselling and testing data as a source of information on HIV prevalence: a systematic review.
  Horyniak D, Guy R, Prybylski D, Hellard M, Kaldor J
  Int J STD AIDS. 2010 May; 21(5):305-311
• Antibody persistence six years after two doses of combined hepatitis A and B vaccine.
  Burgess MA, McIntyre PB, Hellard M, Ruff TA, Lefevre I, Bock HL
  Vaccine. 2010 Mar; 28(10):2222-2226
• Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.
  Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, Hellard M; for the ATAHC Study Group
  Drug Alcohol Depend. 2010 Mar; 107(2-3):244-249
• Surveillance of drug use among young people attending a music festival in Australia, 2005-2008.
  Lim MS, Sacks-Davis R, Aitken CK, Hocking JS, Hellard ME
  Drug Alcohol Rev. 2010 Mar; 29(2):150-156
• Incentive payments to general practitioners aimed at increasing opportunistic testing of young women for chlamydia: a pilot cluster randomised controlled trial.
  Bilardi JE, Fairley CK, Temple-Smith MJ, Pirotta MV, Mc Namee KM, Bourke S, Gurrin LC, Hellard M, Sanci LA, Wills MJ, Walker J, Chen MY, Hocking JS
  BMC Public Health. 2010 Feb; 10:70
• Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
  Dore GJ, Hellard M, Matthews G, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM; Australian Trial In Acute Hepatitis C Study Group
  Gastroenterology. 2010 Jan; 138(1):123-35

2009 (23)

• Sporadic gastroenteritis and recreational swimming in a longitudinal community cohort study in Melbourne, Australia.
  Dale K, Wolfe R, Sinclair M, Hellard M, Leder K
  Am J Epidemiol. 2009 Dec; 170(12):1469-1477
• Factors influencing a self-limiting HIV outbreak among ethnic Vietnamese injecting drug users in Melbourne, Australia.
  Higgs P, Yohannes K, Hellard M, Maher L
  Qual Health Res. 2009 Dec; 19(12):1690-1701
• Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.
  Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ
  PLoS Pathog. 2009 Dec; 5(12):e1000707
• The role of general practitioners in managing and treating hepatitis C.
  Hellard ME, Wang YH
  Med J Aust. 2009 Nov; 191(10):523-524
• Surveillance of STI risk behaviour among young people attending a music festival in Australia, 2005-08.
  Lim MS, Hellard ME, Aitken CK, Hocking JS
  Aust N Z J Public Health. 2009 Oct; 33(5):482-484
• The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.
  Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G, Maher L, Kaldor JM, Dore GJ, Law MG
  J Gastroenterol Hepatol. 2009 Oct; 24(10):1648-1654
• The "work" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV.
  Giles ML, Hellard ME, Lewin SR, O'Brien ML
  AIDS Care. 2009 Oct; 21(10):1230-1237
• The Victorian hepatitis C education program for GPs--an evaluation.
  Wang YH, Guy R, Hellard M
  Aust Fam Physician. 2009 Sep; 38(9):749-752
• Limits to relying on expert information: the Delphi technique in a study of ethnic Vietnamese injection drug users in Melbourne, Australia.
  Nguyen OK, Higgs PG, Hellard ME
  Soc Work Public Health. 2009 Sep; 24(5):371-379
• Hepatitis C treatment for injection drug users: a review of the available evidence.
  Hellard M, Sacks-Davis R, Gold J.
  Clin Infect Dis. 2009 Aug; 49(4):561-573
• TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus.
  Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, McCluskey J
  Immunol Cell Biol. 2009 Aug; 87(6):464-472
• Heroin-gel capsule cocktails and groin injecting practices among ethnic Vietnamese in Melbourne, Australia.
  Higgs P, Dwyer R, Duong D, Thach ML, Hellard M, Power R, Maher L
  Int J Drug Policy. 2009 Jul; 20(4):340-346
• Discrepancies between young people's self-reported sexual experience and their perceptions of 'normality'.
  Lim MS, Aitken CK, Hocking JS, Hellard ME
  Sex Health. 2009 Jun; 6(2):171-172
• Delayed diagnosis of HIV infection in Victoria 1994 to 2006.
  Lemoh C, Guy R, Yohannes K, Lewis J, Street A, Biggs B, Hellard M
  Sex Health. 2009 Jun; 6(2):117-122
• The impact of immigration on the burden of HIV infection in Victoria, Australia.
  Horyniak D, Stoové M, Yohannes K, Breschkin A, Carter T, Hatch B, Tomnay J, Hellard M, Guy R
  Sex Health. 2009 Jun; 6(2):123-128
• Can data from HIV voluntary counselling and testing be used to assess the impact of public health interventions? A literature review.
  Guy RJ, Prybylski D, Fairley CK, Hellard ME, Kaldor J
  Int J STD AIDS. 2009 Jun; 20(6):378-383
• Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005 (REPLY)
  Giles ML, McDonald AM, Elliott EJ, Ziegler JB, Hellard ME, Lewin SR, Kaldor JM
  Med J Aust. 2009 Jun; 190:220-221
• Sex and sport: chlamydia screening in rural sporting clubs.
  Kong FY, Hocking JS, Link CK, Chen MY, Hellard ME
  BMC Infect Dis. 2009 May; 9:73
• Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
  Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK
  J Infect. 2009 May; 58(5):375-382
• Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
  Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, McCaughan G, Sasadeusz J, White P, Rawlinson W, Lloyd A, Kaldor J, Dore GJ
  Clin Infect Dis. 2009 Mar; 48(5):650-658
• Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users.
  Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N, Jauncey M, Conroy A, Lewis J, Aitken C
  Drug Alcohol Depend. 2009 Feb; 100(1-2):9-16
• Antenatal screening practice for infectious diseases by general practitioners in Australia.
  Giles ML, Pedrana A, Jones C, Garland S, Hellard M, Lewin SR
  Aust N Z J Obstet Gynaecol. 2009 Feb; 49(1):39-44
• Does Information about IDUs' Injecting Networks Predict Exposure to the Hepatitis C Virus?
  Aitken CK, Lewis JA, Hocking JS, Bowden DS, Hellard ME
  Hepatitis Monthly. 2009 Jan; 9(1):17-23

2008 (19)

• Using a surveillance system to identify and treat newly acquired hepatitis C infection.
  Walsh N, Lim M, Hellard M
  J Gastroenterol Hepatol. 2008 Dec; 23(12):1891-1894
• High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
  Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, Drummer H, Hetlard M
  Hepatology. 2008 Dec; 48(6):1746-1752
• Working with West African migrant communities on HIV prevention in Australia.
  Lemoh C, Biggs BA, Hellard M
  Sex Health. 2008 Dec; 5(4):313-314
• Gender, culture and harm: an exploratory study of female heroin users of Vietnamese ethnicity.
  Higgs P, Owada K, Hellard M, Power R, Maher L
  Cult Health Sex. 2008 Oct; 10(7):681-696
• Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response.
  Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D, Hellard M, McCluskey J, Torresi J, Bharadwaj M
  Clin Immunol. 2008 Sep; 128(3):329-339
• Registered post achieved a higher response rate than normal mail--a randomized controlled trial.
  Pedrana A, Hellard M, Giles M
  J Clin Epidemiol. 2008 Sep; 61(9):896-899
• Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005.
  Giles ML, McDonald AM, Elliott EJ, Ziegler JB, Hellard ME, Lewin SR, Kaldor JM
  Med J Aust. 2008 Aug; 189(3):151-154
• Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region.
  Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S, Lim M, Vonthanak S, Lal L, Sarim C, Huffam S, Li P, Imran D, Lewis J, Lun WH, Kamarulzaman A, Tau G, Ali ST, Kishore K, Bain MP, Dwyer R, McCormack G, Hellard M, Cherry C, McArthur J, Wesselingh S
  Neurology. 2008 Jul; 71(1):50-56
• A cross-sectional survey of young people attending a music festival: associations between drug use and musical preference.
  Lim MS, Hellard ME, Hocking JS, Aitken CK
  Drug Alcohol Rev. 2008 Jul; 27(4):439-441
• Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
  Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D, Hellard M, Ffrench R
  Influenza Other Respi Viruses. 2008 Jul; 2(4):115-125
• Characteristics of HIV diagnoses in Australia, 1993-2006.
  Guy RJ, McDonald AM, Bartlett MJ, Murray JC, Giele CM, Davey TM, Appuhamy RD, Knibbs P, Coleman D, Hellard ME, Grulich AE, Kaldor JM
  Sex Health. 2008 Jun; 5(2):91-96
• Enhanced case detection for newly acquired hepatitis C infection: epidemiological findings and health service implications.
  Guy R, Devadason D, Lim M, Higgins N, Pedrana A, Gibson K, Lewis J, Spelman T, White B, Kaldor J, Hellard M
  Commun Dis Intell. 2008 Jun; 32(2):250-256
• Risk behaviours and blood borne virus exposure for transient workers in rural Victoria.
  Pedrana A, Aitken C, Higgs P, Hellard M
  Aust J Rural Health. 2008 Jun; 16(3):143-149
• SMS STI: a review of the uses of mobile phone text messaging in sexual health.
  Lim MS, Hocking JS, Hellard ME, Aitken CK
  Int J STD AIDS. 2008 May; 19(5):287-290
• Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user.
  Aitken CK, Tracy SL, Revill P, Bharadwaj M, Bowden DS, Winter RJ, Hellard ME
  J Clin Virol. 2008 Apr; 41(4):293-296
• Buprenorphine injection in Melbourne, Australia - an update.
  Aitken CK, Higgs PG, Hellard ME
  Drug Alcohol Rev. 2008 Mar; 27(2):197-199
• Barriers to the delivery of the hepatitis B birth dose: a study of five Papua New Guinean hospitals in 2007.
  Downing SG, Lagani W, Guy R, Hellard M
  P N G Med J. 2008 Mar; 51(1-2):47-55
• Integrating enhanced hepatitis C testing and counselling in research.
  Winter R, Nguyen O, Higgs P, Armstrong S, Duong D, Thach ML, Aitken C, Hellard M
  Int J Drug Policy. 2008 Feb; 19(1):66-70
• The rise of infectious syphilis in Victoria and the impact of enhanced clinical testing.
  Allen K, Guy R, Leslie D, Goller J, Medland N, Roth N, Lewis J, Hellard M
  Aust N Z J Public Health. 2008 Feb; 32(1):38-42

2007 (14)

• Modelling the hepatitis C virus epidemic in Australia.
  Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M
  Drug Alcohol Depend. 2007 Dec; 91(2-3):228-235
• HIV diagnoses in Australia: diverging epidemics within a low-prevalence country.
  Guy RJ, McDonald AM, Bartlett MJ, Murray JC, Giele CM, Davey TM, Appuhamy RD, Knibbs P, Coleman D, Hellard ME, Grulich AE, Kaldor JM
  Med J Aust. 2007 Oct; 187(8):437-440
• Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
  Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; on behalf of the ATAHC Protocol Steering Committee
  Int J Drug Policy. 2007 Oct; 18(5):447-451
• Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.
  Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ
  AIDS. 2007 Oct; 21(15):2112-2113
• Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications.
  Ayton DR, Guy RJ, Woolley IJ, Hellard ME
  Sex Health. 2007 Sep; 4(3):209
• A new surveillance system for monitoring HIV infection in Victoria, Australia.
  Guy R, Lim MSC, Wang YH, Medland N, Anderson J, Rothe N, Hellard ME
  Sex Health. 2007 Sep; 4(3):195-199
• Tattooing in prisons--not such a pretty picture.
  Hellard ME, Aitken CK, Hocking JS
  Am J Infect Control. 2007 Sep; 35(7):477-480
• What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians.
  Giles ML, Garland SM, Lewin SR, Hellard ME
  AIDS. 2007 Jul; 21(12):1601-1606
• The feasibility of recruiting young men in rural areas from community football clubs for STI screening.
  Gold, J, Hocking, J, Hellard, M
  Aust N Z J Public Health. 2007 Jun; 31(3):243-246
• Chlamydia trachomatis prevalence in heterosexual men in Melbourne: a community-based study.
  Wade AJ, Hocking LS, Hellard ME
  Sex Health. 2007 Jun; 4(2):137-138
• Sexual-risk behaviour, self-perceived risk and knowledge of sexually transmissible infections among young Australians attending a music festival.
  Lim MS, Hellard ME, Aitken CK, Hocking JS
  Sex Health. 2007 Mar; 4(1):51-56
• Risk factors for incident HIV infection in men having sex with men: a case-control study.
  Read TRH, Hocking J, Sinnott V, Hellard M
  Sex Health. 2007 Mar; 4(1):35-39
• Reliability and validity of the Kessler 10 and Patient Health Questionnaire among injecting drug users.
  Hides L, Lubman DI, Devlin H, Cotton S, Aitken C, Gibbie T, Hellard M
  Aust N Z J Psychiatry. 2007 Feb; 41(2):166-168
• Blood-borne viruses and risk behaviours among injecting drug users recruited from needle and syringe programs in Victoria's eastern metropolitan region
  Lim MS, Sundaram K, Aitken CK, Hellard ME
  Aust J Prim Health. 2007 Jan; 13(3):69-76

2006 (8)

• The prevalence and risk behaviours associated with the transmission of blood-borne viruses among ethnic-Vietnamese injecting drug users.
  Hellard ME, Nguyen OK, Guy RJ, Jardine D, Mijch A, Higgs PG
  Aust N Z J Public Health. 2006 Dec; 30(6):519-525
• Chlamydia testing in general practice - a survey of Victorian general practitioners.
  Hocking JS, Lim MS, Vidanapathirana J, Read TR, Hellard M
  Sex Health. 2006 Dec; 3(4):241-244
• A chlamydia prevalence survey of young women living in Melbourne, Victoria.
  Hocking JS, Willis J, Tabrizi S, Fairley CK, Garland SM, Hellard M
  Sex Health. 2006 Dec; 3(4):235-240
• Acute Hepatitis C treatment Uptake in the Victorian Population.
  Walsh N, Lim M, Nguyen O, Von Bibra S, Dore G, and Hellard M
  18th Annual Conference. 2006 Oct; Abstract page 153
• The evidence for a change in antenatal HIV screening policy in Australia.
  Giles ML, Hellard ME, Lewin SR, Mijch AM
  Med J Aust. 2006 Aug; 185(4):217-220
• Postal surveys of physicians gave superior response rates over telephone interviews in a randomized trial.
  Hocking JS, Lim MS, Read T, Hellard M
  J Clin Epidemiol. 2006 May; 59(5):521-524
• Impact of an education campaign on management in pregnancy of women infected with a blood-borne virus.
  Giles ML, Garland SM, Grover SR, Lewin SR, Hellard ME
  Med J Aust. 2006 Apr; 184(8):389-392
• A profile of HIV testing in Victoria, 1984 to 2004.
  Lim M, Guy R, Hellard M
  Commun Dis Intell. 2006 Jan; 30(3):366-372

2005 (5)

• The case of the disappearing teaspoons: longitudinal cohort study of the displacement of teaspoons in an Australian research institute.
  Lim MSC, Hellard ME, Aitken CK
  BMJ. 2005 Dec; 331(7531):1498-1500
• Blood-borne viral and sexually transmissible infections among psychiatric populations: what are we doing about them?
  Hercus M, Lubman DI, Hellard M
  Aust N Z J Psychiatry. 2005 Oct; 39(10):849-855
• Sustained increase in infectious syphilis notifications in Victoria.
  Guy RJ, Leslie DE, Simpson K, Hatch B, Leydon J, Hellard ME, Kelly HA
  Med J Aust. 2005 Aug; 183(4):218
• Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay.
  Guy RJ, Breschkin AM, Keenan CM, Catton MG, Enriquez AM, Hellard ME
  J Acquir Immune Defic Syndr. 2005 Apr; 38(4):495-499
• A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.
  Mijch A, Sasadeusz J, Hellard M, Dunne M, McCaw R, Bowden S, Gowans EJ
  Antivir Ther. 2005 Jan; 10(2):277-284

2004 (9)

• Change in hepatitis C virus genotype in injecting drug users.
  Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, Crofts N, Hellard M
  J Med Virol. 2004 Dec; 74(4):543-545
• The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia.
  Ryan CE, Elliott JH, Middleton T, Mijch AM, Street AC, Hellard M, Crofts N, Crowe SM, Oelrichs RB
  AIDS Res Hum Retroviruses. 2004 Dec; 20(12):1364-1367
• Rising HIV infection in Victoria: an analysis of surveillance data.
  Hocking J, Keenan C, Catton M, Breschkin A, Guy R, Hellard M
  Aust N Z J Public Health. 2004 Jun; 28(3):217-219
• The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities.
  Hellard ME, Hocking JS, Crofts N
  Epidemiol Infect. 2004 Jun; 132(3):409-415
• HIV and pregnancy in Australia.
  Giles ML, Mijch AM, Garland SM, Grover SR, Hellard ME
  Aust N Z J Obstet Gynaecol. 2004 Jun; 44(3):197-204
• An audit of obstetricians' management of women potentially infected with blood-borne viruses.
  Giles ML, Sasadeusz JJ, Garland SM, Grover SR, Hellard ME
  Med J Aust. 2004 Apr; 180(7):328-332
• Indications of immune protection from hepatitis C infection.
  Aitken CK, Bowden S, Hellard M, Crofts N
  J Urban Health. 2004 Mar; 81(1):58-60
• Rising HIV infections in Victoria, the need for a new approach to preventative interventions.
  Guy R, Hellard M
  Sex Health. 2004 Feb; 1(2):69-71
• HIV in prison: what are the risks and what can be done?
  Hellard ME, Aitken CK
  Sex Health. 2004 Jan; 1(2):107-113

2003 (3)

• Risk factors leading to Cryptosporidium infection in men who have sex with men.
  Hellard M, Hocking J, Willis J, Dore G, Fairley C
  Sex Transm Infect. 2003 Oct; 79(5):412-414
• Hepatitis C and pregnancy: an update.
  Giles M, Hellard M, Sasadeusz J
  Aust N Z J Obstet Gynaecol. 2003 Aug; 43(4):290-293
• Investigation of infection control practices and knowledge of hepatitis C among body-piercing practitioners.
  Hellard M, Aitken C, Mackintosh A, Ridge A, Bowden S
  Am J Infect Control. 2003 Jun; 31(4):215-220

2002 (1)

• The rate of gastroenteritis in a large city before and after chlorination.
  Hellard ME, Sinclair MI, Dharmage SC, Bailey MJ, Fairley CK
  Int J Environ Health Res. 2002 Dec; 12(4):355-360

2001 (2)

• A randomized, blinded, controlled trial investigating the gastrointestinal health effects of drinking water quality.
  M E Hellard, M I Sinclair, A B Forbes, C K Fairley
  Environ Health Perspect. 2001 Aug; 109(8):773-778
• Methods used to maintain a high level of participant involvement in a clinical trial.
  M E Hellard, M I Sinclair, A B Forbes, C K Fairley
  J Epidemiol Community Health. 2001 May; 55(5):348-351

2000 (2)

• HIV associated cytomegalovirus retinitis in Melbourne, Australia.
  C L Cherry, A M Mijch, J F Hoy, A J Hall, M E Hellard, M Bryant, B DeGraaff, C K Fairley
  Sex Transm Infect. 2000 Jun; 76(3):221
• Prevalence of enteric pathogens among community based asymptomatic individuals.
  M E Hellard, M I Sinclair, G G Hogg, C K Fairley
  J Gastroenterol Hepatol. 2000 Mar; 15(3):290-293

1998 (3)

• Protozoa in drinking water: is legislation the best answer?
  M I Sinclair, C K Fairley, M E Hellard
  Med J Aust. 1998 Sep; 169(6):296-297
• Detection of an aberrant motile larval form in the brain of a patient with neurocysticercosis.
  M E Hellard, A C Street, P D Johnson, E A Popovic, G V Brown
  Clin Infect Dis. 1998 Aug; 27(2):391-393
• Tuberculous pancreatic abscess in an HIV antibody-negative patient: case report and review.
  A W Jenney, R W Pickles, M E Hellard, D W Spelman, A J Fuller, W J Spicer
  Scand J Infect Dis. 1998 Jan; 30(2):99-104

1997 (6)

• Safe drinking water.
  A A Padiglione, M E Hellard, M I Sinclair, C K Fairley
  Med J Aust. 1997 Jun; 166(12):670
• Drinking water and microbiological pathogens--issues and challenges for the year 2000.
  M E Hellard, M I Sinclair, C L Streeton, C K Fairley
  J Public Health Med. 1997 Jun; 19(2):129-131
• Pancreatic tuberculosis (TB) in HIV infection.
  A Jenney, R Pickles, M Hellard, D Spelman, A Fuller, W J Spicer
  Aust N Z J Med. 1997 Jun; 27(3):349-350
• Cryptosporidiosis in patients with AIDS.
  R L Stuart, M E Hellard, D Jolley, D Spelman, J Hoy, E M Stevenson, M T Yates, N J Ryan, C K Fairley
  Int J STD AIDS. 1997 May; 8(5):339-341
• Gastroenteritis in Australia: who, what, where, and how much?
  M Hellard, C K Fairley
  Aust N Z J Med. 1997 Apr; 27(2):147-149
• Totally implantable venous access device infections in patients with AIDS.
  M Hellard, A Fuller, D Spelman, W J Spicer, R Pickles, A Jenney
  AIDS. 1997 Apr; 11(5):697-698

News Articles (89)

2020 (1)

• Burnet committed to hep C elimination

2019 (11)

• The case for a hepatitis C vaccine
• Burnet partners with Egypt for hepatitis workshop
• First national hepatitis report reveals progress
• Primary healthcare effort needed to achieve hep C elimination
• Burnet at IAS 2019
• Hepatitis C treatment in primary care crucial to elimination
• Later HIV diagnoses for women
• International Women's Day event focuses on young women most-at-risk
• At the forefront of hepatitis elimination
• Australia Day Honours for Burnet staff and associates
• Lancet Commission on viral hepatitis

2018 (14)

• Ned's award for research excellence
• WISH for hepatitis elimination is achievable
• The curious case of the missing workplace teaspoons
• Prestigious Fellowship for Professor Margaret Hellard
• ACCESS a perfect ten
• Preventing and responding to opioid overdose in Victoria
• EC Australia: The missing link to hepatitis C elimination
• Hepatitis elimination efforts in great hands
• World Hepatitis Day: Optimism about eliminating this silent killer
• Burnet at AIDS 2018!
• Scholarships for Burnet alumni
• Eliminating viral hepatitis a major focus at WISH 2018
• Vale Jenny Kelsall
• Landmark study into adolescent health in Myanmar

2017 (14)

• U=U addressing HIV stigma
• Hep C Testing: The front line
• Positive signs from hepatitis summit
• Vale Levinia Crooks
• Burnet World Hepatitis Day Symposium
• Hep C treatment decline prompts new call out
• The case for new hepatitis C treatments
• Pornography the norm for young Australians
• WHO appointment for Professor Margaret Hellard
• Burnet research at World Congress on Public Health
• Leading roles for Burnet at World Congress on Public Health
• Hep C virus exposed to attack
• Hepatitis guidelines a step towards elimination
• Hep C focus of $7m NHMRC grant

2016 (15)

• Inaccurate reporting creates further stigma for hep C patients
• NHMRC grants for Burnet researchers
• Hep C: Elimination is the Goal
• PrEP study proving highly attractive
• Survey reveals pornography's mixed impacts
• Victorian hepatitis strategy welcomed
• Burnet launches Eliminate Hep C strategy
• 2020 vision for Hep C elimination
• Hep C co-EC study showcased at AIDS 2016
• Towards an HIV Cure 2016: global strategy released
• NHMRC grant to assist hepatitis C research
• Australia a potential world leader to eliminate hepatitis C
• Historic partnership aims to end hep C within a decade
• Landmark day with listing of hepatitis C drugs on PBS scheme
• TAP Study: A key to hepatitis C elimination

2015 (9)

• HCV cure drugs available to all Australians
• Burnet's NHMRC success rate among Australia's best
• CREIDU Colloquium 2015: Five minute talk can save a life
• Hepatitis C elimination viable
• Turning point for hepatitis treatment
• PRONTO! funding welcomed
• Burnet celebrates International Women's Day
• Dame Carol Kidu Patron for HMHB
• Key role for Hep C Inquiry

2014 (14)

• 2014 in Review: January - June
• 2014 In Review: July - December
• Study aims to eliminate hepatitis C in Australia
• Burnet studies shed light on sexual behaviour of teenagers
• World Hepatitis Day: Hepatitis C elimination is possible
• AIDS 2014: Conversation Hour at Burnet Institute
• AIDS 2014: CREIDU Colloquium
• Call to Action to Scale up Global Hepatitis Response
• Jim and Margaret Beever Fellowship awarded
• First-ever hepatitis C treatment guidelines released
• Test it. Treat it. Beat it. Call for rapid testing to end hepatitis
• Eliminating hepatitis C - an ambitious but achievable goal
• Burnet celebrates International Women's Day
• Chloe Bryce-Shorten joins call for health equality for women

2013 (5)

• Burnet launches Campaign to STOP TB
• Congratulations to Burnet's NHMRC grant recipients
• New drugs and an effective vaccine could lead to hepatitis C eradication
• New hepatitis C treatments to be listed on the Pharmaceutical Benefits Scheme
• Reaching Out: Working with Melbourne’s most vulnerable

2012 (4)

• HIV is still here! Burnet helps launch World AIDS Day 2012
• Call for Action on Viral Hepatitis: the Auckland Statement
• Suboxone® in Australia: focus of CREIDU Colloquium
• Treating injecting drug users vital in reducing hepatitis C

2011 (2)

• Burnet sexual health research showcased in Canberra
• Injecting drug use the focus of new Centre for Research Excellence